SSS乌云满天H1SG5

recently, UT Starcom announced the appointment of chief operating officer of Lu Ying and Lu Ying will take over a certain period of time, CEO of UT Starcom. Previously, UT Starcom also announced, broadcast and broadband will be the two main directions of its future. In response, Lu Ying on March 26 this morning a guest Sina chat topic.

Video: Interview with UT Starcom Media COO Lu Ying Source: Sina Technology

guests Description:

Lu Ying, UT Starcom chief operating officer of Lu Ying, has a wealth of multinational corporations work experience in the telecommunications, optoelectronics, and investment project management has over 25 years of experience.

joined UT Starcom ago, Lu eagle in the world’s leading optical device company Source Photonics as co-chief operating officer and general manager of China. Prior to joining Source Photonics, he Fiberxon company (in July 2007 sold to MRV Communications Co., Ltd.) in various capacities, including CEO, COO and vice president of marketing and sales operations. In September 2001 before adding Fiberxon, Lu Ying worked for US Business Networks Ltd (MeetChina.com), 2000 年 3 月 至 2001 年 5-month period as director of business strategy development. From May 1988 to July 1998, he worked for China National Technical Import and Export Corporation, as a variety of management positions. Lu Ying graduated from the Huazhong University of Science degree in Electrical Engineering, followed by the University of Southern California Master of Business Administration (MBA) degree.

wonderful view Abstract:

• in general, called the return to China. First of all I want to tell you that reunification does not mean that only do the Chinese market,fengshui, returned to China means that we put the company’s headquarters, R & D team, and our emphasis on further strengthening the Chinese market.

• I am pleased to tell you that our new management team, almost entirely composed by the Chinese people, which UT Starcom is the first time in history. I believe this team will be more understanding of the situation in China, a better understanding of our employees and our customers.

• For the future, we grasp the two aspects, first, focus, and the second is innovation. And difficulties experienced after some adjustments, maybe UT is not like some of our peers as providing Quanchengquanwang of telecommunications solutions, but we have spent a lot of resources. And will continue to invest in the future, focus on one aspect of this building we NGB, to our limited resources into this area go, it does fine, good, real close to our customers needs and service needs, in order to improving our competitiveness.

Following interviews with UT Starcom chief operating officer of Lu Ying Record

the right to host static: you Sina users Hello everybody, welcome to Sina Technology video studio, I chaired Static human rights. Concerned friends have noticed a dynamic industry, and in February, when Beijing Yizhuang International Investment and Development Co., Ltd. has already become the UT Sidakangda strategic cooperation agreement, along with two other fund companies to participate, completed a restructuring plan . Recently we have received the latest news, UT Starcom has been formally appointed as the company’s chief operating officer, Lu Ying, a comprehensive broadband business unit responsible for UT Starcom, multimedia communications division, the global supply chain and marketing and sales in China business and report directly to CEO and president of UT Starcom Pete • Blackmoore report. UT Starcom today invited Lu Ying, Chief Operating Officer to communicate with you.

Lu Ying: Thank you.

the right to host static: I just introduced you to the current title is chief operating officer of UT Starcom, is COO. At first I found when you chat, you are to the UT Starcom is 4 weeks, beginning one month before taking office, and on the UT Starcom The corporations, or, including the industry’s business Ye Hao, understand many, is a fast learning month.

give us talk about this a month, your feelings and experiences?

Lu Ying: I think I actually feel most of our employees and customers, on the UT Starcom concern. Every time I communicate with the staff, I see their eyes, I could feel the love of their company, this is the case, they really really want the company to get better.

I went to visit our customer, in exchange with them, they also showed appreciation to the UT and the difficulties some time ago Unfortunately, it was very clear and strong desire, willingness to support UT Starcom, and would like to see to its feet again.

the right to host static: Although only a few a month’s time, Lu has been on the UT Starcom always very affection.

the first time we SAN UT Starcom is the first reorganization of the information received, and were reported. For details of the reorganization of UT Starcom, I believe many users are very looking forward you to live today, the ability to take this opportunity to us about the details of the strategic restructuring of the situation?

Lu Ying: three aspects, the first after this round of investment, is our finance company’s board of directors for a transformation; The second is the company’s management team also has a transformation; final our structure and strategy adjustments, should be from three terms.

first in terms of the company’s board of directors, through this financing, we understand the situation in China introduced the three to understand the Chinese market of some senior people to enrich our board of directors, the board will have two of the original Board of Directors resigned. The introduction of such new directors as Mr. Du Baichuan, he is broadcasting industry experts, the industry is high profile, I do not have more introduced. Serious and International Mr. Li Xiaoping, is Serious and International Vice President responsible for investment and development of Beijing’s development policies is very familiar with the understanding, management is also very experienced. There is also the capital of Mr. Huang Shaoqiu Yellowstone, Yellowstone Capital is actually very important to promote the restructuring of institutions, they will come in to provide more strategic value.

Secondly, in the company’s management, you also mentioned,上善若水, the Board appointed me to enter the company, and in the future will take over the whole of the operations management company, be said to be shouldering a heavy burden. In addition, the Company’s original overseas executives, through a period of transition period, will gradually leave. The new management of the remaining core of the current by UT Starcom business, market, consisting of the financial aspects.

I am pleased to inform you that our new administrative team, almost entirely composed by the Chinese, UT’s history is the first time. I believe this team will be more understanding of the situation in China, a better understanding of our employees and our customers.

the right to host static: Just to tell you the total Lu, mainly some of the appointment of personnel changes. Among the specific this month, due to changes in these people, bringing the company’s business strategy and direction for the development of what will change accordingly?

Lu Eagle: This is my third point.

general, called the return to China. First of all I want to tell you that reunification does not mean that only do the Chinese market, returned to China means that we put the company’s headquarters, R & D team, and our emphasis on further strengthening the Chinese market. This time after the transaction, will move their headquarters to Beijing, and further enrich our Hangzhou, two major R & D center in Shenzhen. Indeed UT until now, the international market is still doing good, the Chinese market has experienced the difficulties of PHS, the once somewhat weak, which means that we return to China once the Chinese market once again to strengthen our market and customers commitment, and investment in the market.

the right to host static: In fact, the total mentioned earlier Lu returned to China this trend. China this year to see if that changes the industry may be concerned about friends in the industry would have such feelings, is this year’s Triple Play is by the State Council, Ministry of Industry and SARFT and great support, including policy and funding and so these aspects. Triple play is the trend in China, will give UT Starcom what kind of opportunities? You return to China this kind of action will bring the benefits of what?

Lu Ying: It should be said three are integrated to the UT a rare opportunity, or that we are really lucky, right time. January State Council issued a decision to promote the triple play, early in February UT announced our new strategic adjustment, a good stepping point, in fact, before we have done a lot of preparation.

triple play, we understand, is a party and the state to further promote domestic economic development, let the people enjoy a higher quality, lower cost of entertainment, information services. So for us, a really unique opportunity, so we are very pleased to see this, and whom ready.

the right to host Static: When it comes to grasp this opportunity, we are concerned that the company’s development strategy from the point of view, the UT Starcom Telecom started in the broadcasting industry to grow, play the sound of the wind water from, but also by the triple play of the wind. UT Starcom you share the essence of the broadcasting business and stronger? We understand the issues from another perspective, why the countries pushing triple play, when you think with the cooperation, Chinese and the UT Starcom Where? Where do you send the next power?

Lu Ying: Triple Play countries is to eliminate trade barriers, these barriers are due to historical reasons the various aspects of the formation. Terms of the UT, or other company dedicated to communication in terms of vendors, from telecommunications and broadcasting is technically not divided, how we do things like high efficiency, low-cost transport service to provide information. So technically integrated, business is indeed very different. For example, our telecommunications industry, mainly focusing on information services, individuals or between groups of information services. We are carrying the radio and television for more video services, broadcasting services, while public opinion and values bearing set of social responsibility. I believe the industry may be due to the difference between this result.

UT in 5 years ago, or even earlier time, the world’s first developed out of IPTV technology, IPTV is actually a popular name for later, Zhen Zheng Wang Luo essence of an efficient video push and Fenfafuwu I believe this may be our earliest connection with the broadcast services. Based on this, our broadband access, transmission and network development, the gradual formation of our radio and television services, features and advantages.

the right to host static: Speaking of which, Lu Zonggang it also tells us about the development trend of the industry from a different angle, from the more recent concern to begin with CCBN in broadcasting development. They said that when the inside can also be found with the total, said Lu Coincidence some of the information industry. This year’s CCBN’s size and the degree of concern over previous years, the broadcasting company is using this opportunity to publicize and promote their own advantage. I have to do with a share of total Lu, a three-day show down what you feel? You just talked about the industry trends, show you how the exchange is like the time to explore?

Lu Ying: show really busy these days, I believe that my first feeling is that the Government’s decision is correct and appeal. This is the hottest I’ve seen the previous one, UT’s booth was busy all the time I squeeze into the crowded not.

The second point I would like to favorable factors to describe the show, “days\so that people integrate the three networks of the future with confidence, and convert everyone to participate in this exhibition of great enthusiasm.

“location\trend. We did not clear until the last of the State Council are in the Shi Jin to do, but the direction of this effort together in the same direction, that is triple play.

then “and” We can see from the show very well, everyone can see the face was warm, kind of look, kind of input, that is my feeling at the CCBN exhibition, can be said to be very successful next exhibition.

the right to host static: Lu just three major general from the perspective of opportune to do the sharing, the big trend, we are more concerned about the final development of the company is to implement the product, So in the current exhibition, UT Starcom What are the main products on display? What kind of products can reach as you just said does not stand all crowded into the extent of product innovation for them?

Lu Ying: UT Starcom on display this time in our broadcasting of all NGB building targeted solutions, the idea is not to say we want to sell a particular product, or a set of products, we would like to more practical understanding of how broadcast technology and service needs to provide a comprehensive solution.

first load level in the business, UT Starcom UT Starcom based on the greatest advantage, and video push system, interactive TV for the needs of radio and television made a further improvement and optimization, out of the interaction TV’s comprehensive solution to adapt to different radio and television networks. We know that every region Broadcasting Network access methods, and even some standards are slightly different, we provide a complete solution.

In addition, we also propose a solution for all of the terminal to meet the needs of different users, from the most standard and most simple, easy to use program to a diverse, full-service high-end family service centers. For example, our family TV set-top box terminals this exhibition, and we played name is Le Xuan, including not only the video shows, interactive, and many audiences when, sitting there for a very long time, are not willing to go, it is our view to a very happy thing.

We also propose a network solution, we come to the (EPON + EOC) of the integrated program, our Innovation Award in the technology solutions are also exhibited. We also display the PTN, packet transmission, this is our latest products, from TV along to the network core, UT took out a full comprehensive program.

the right to host static: Lu general description of the product trends, we first referred to UT Starcom’s restructuring may be in the past, said the exhibition and the products that are now, the next section we want to eyes on the future. We look to the future industry trends what are thinking? UT Starcom have many advantages and the essence of the above in the three are integrated and the NGB will have a good trend, how kind of you to grasp this in the future opportunities?

Lu Ying: We take two aspects,平平淡淡才是真, first, focus, and the second is innovation. And difficulties experienced after some adjustments, maybe UT is not like some of our peers, as the whole entire telecom solution, but we have spent a lot of resources. And will continue to invest in the future, focus on building our NGB this regard, our limited resources into this area go, it does fine, good, real close to our customers needs and service needs, in order to improve the competitiveness of our products.

followed by innovation, innovation is the core value of UT history, the most important part, not only technical innovation, more market services, or even all aspects of company operations to achieve innovation. Its orientation is only one, is to provide our customers with the best service and the best products.

the right to host static: Speaking of which, you just mentioned that the industries, the peer trend, we would also like to look at how UT Starcom see competition in the industry, in the end we would also like you to of the triple play, NGB industries, UT Starcom see how your competitors? After you have gone through restructuring, compared with competitors advantage? Where weaknesses? How should this kind of competition in the future?

Lu Eagle: Of course, we have a ZTE, Huawei, a lot of foreign telecom giants. UT Starcom is because the scale of the reason can not compete with them, but based on our field and innovative spirit, I believe we still can you win a fight. This “fight” is the normal market competition, not any particular one market sector or small enterprises to participate in a two can do together, and only a concerted effort into this area, healthy competition, to this development of the industry lead on the healthy development. I like the words of our sales force, called the Friends of the business, not called competitors, we put together, work together to integrate the three networks and the construction of NGB head to a new height, I would like to see this.

the right to host Static: Thanks Lu general. Although Lu UT Starcom’s chief operating officer of the total arrival only 4 weeks time, we hear he has just told us of, you can find, whether it is the challenge for the company’s current or future opportunities to meet to are filled with the full knowledge and full confidence. We also know that overall responsibility for the future of the Federation of UT Starcom Lu overall business management. We also hope that a month later, a longer time in the future which, can bring better development of UT Starcom position, also ushered in light of China’s triple play opportune better opportunities for development, pre- I wish you success.

Lu Ying: Thank you.

interview with UT Starcom Media COO Lu Ying Source: Sina Technology Play Video> Related reading: UT Starcom Lu Ying was appointed Chief Operating Officer
相关的主题文章：

• Terry Gou, Foxconn and the earthquake area to cont
• Chinese input method and then hearing the first ca
• Peng Lei Bao CEO pay that Miss soft dialect of Ali

Mobile payment can be related to daily payment and settlement integrated in a card. (Profile picture)

□ edition the author information Times reporter Qiao Qianqian

do not need bus or metro card wallet, only through the “brush” mobile phone will be able to achieve small debit card, credit card payment function. Shanghai World Expo opening draws near, take the opportunity to promote mobile phone payment service, has been in the industry interpreted as a “Business Breakthrough\Carried out in the mobile phone to pay at the same time, while also actually running CUP. It is understood that in mid-March, the concept has been placid, mobile payment has become a hot spot capital market speculation.

stake in Shanghai Pudong Development move intended to break through

It is understood that the mobile phone payment service has been launched 6 years, but this has not been plain sailing. While the business development in China road twists and turns, but this year, Shanghai Pudong Development Bank China Mobile stake in mobile payment business seems to be a landmark event in the further development.

some analysts said, after BCT, various telecom operators and banks in the mobile payment business promotion is not successful, due to an existing credit card and banking conflict of interest such as business, bank support for not. “Mobile payment involves small payments, and banks have little to do, not monetary policy is also violated, but if it is large to pay, then the platform started to rely on banks.” Letter of the securities on the electronics industry, said researcher Li Zhi.

and move to Pudong Development Bank shares can solve this problem, China Mobile announced a share subscription agreement shows Shanghai Pudong Development Bank China Mobile shares subscribed by the Guangdong Mobile in cash upon closing, Guangdong Mobile will be paid on the value of its internal resources. Moving announcement also revealed that China Mobile and Guangdong Mobile and Pudong Development also signed the same day exhibition MOU, signed a strategic cooperation under the memorandum, both sides intend to jointly develop mobile financial services and mobile e-commerce started to work closely in areas such as mobile payments are not limited to cooperation business, mobile banking card business, mobile transfer services, and other forms of mobile financial services and mobile commerce.

“business development in the mobile payment in Japan is more mature, dominant, carriers will be acquired early in banking, followed by business through the acquisition of shares in the network structure, better integration of resources completed . “Mr Lee said, Japan and China in fact is in accordance with the mode of development.

Orient Securities analyst Zhou Jun, a senior communications industry that, in 2010 in mobile phone payment service will include the Group KPI evaluation system, focusing on promotion, in recent years included in the Group’s operations are to achieve KPI extraordinary development reference to this development model, that the mobile payment service users to achieve explosive growth this year, the number of users will reach 10 million.

POS replacement cost of the test machine operators

While the market in mobile ambitious,wedding, but the development direction of mobile payment is still unclear. Some analysts have pointed out that China Mobile would like to take the Expo started to break out of the brush at the Expo during the launch of mobile phone purchase tickets and take mass transit, in cooperation with commercial operators such as POS machine brush machine consumer business, to become a major highlight of the Expo. But the recent media reports, China Mobile within the development direction of mobile payment still controversial, as close to pay higher costs, tend to develop long-range views of an advantage to pay.

“Although RF-SIM program has some advantages, but their frequency is maverick, once developed mobile payment, POS machines and other hardware devices are required for replacement cost carriers have become consideration. “Mr Lee said the current understanding is that the provincial company has not received notice of cessation of business, can only say that China Mobile executives are also discussed.

operators actually run with the CUP mobile payment

carried out in the mobile phone to pay at the same time, CUP are actually running. March 16 this year, Consortium announced a new generation of mobile payment pilot service area expanded to Shanghai, Shandong, Ningbo, Hunan, Sichuan, Shenzhen and six provinces.

4 16, China Union Pay has just join the bank and other five commercial banks starting in Changsha, Changsha public financial standards card at the same time, the carrier card will be the people of Changsha, China Union Pay and China Unicom to jointly promote in Hunan CUP mobile payment service. Opened the business user applications, without having to change phone numbers, as long as the card-issuing bank through the financial smart card will be customized to your cell phone can be. Issuance volume during the year is expected to reach 1 million. It is the November 2009 China Unicom, China Union Pay and comprehensive strategic cooperation agreement signed since the first mobile payment made substantial progress in the field. China Union Pay and China Unicom to promote mobile payment service will self-evident.

Mr Lee said that no matter what kind of mobile payment options to take, will face cross-sectoral coordination problems. CUP financial strength as the problem of relying on the development of mobile payment services CUP difficult, but the POS machine shops are CUP’s resources, while China Mobile will have a larger user capacity and capital strength, the best way is to move , CUP, banks tripartite consultations for this problem, based on the established interests, while ensuring mutual interests, but also to promote industrial development, as this is most important.

Status

capital market has been stirred

in the secondary market, mobile payment concept has undergone a speculation. Statistical classification of information according to WIND, a company currently in Shanghai and Shenzhen in line with the concept of mobile payment companies including Sunlord Electronics, Electronic cards, Hong Keung E, Eastcom Peace and long power technology, the shares were in the first quarter adverse economic rise. 3 months 17, Eastcom Peace, New World, Xiamen Xindeco,cateatfish, Gu Yuan Wang, Hong-shares and other related high stocks of collective daily limit, while the long electric technology is a daily limit of two consecutive days.

with analysts that the concept of mobile payment through a speculation has been high valuations, should be careful chasing, but once the mobile payment industry developed, the industry will be great investment opportunities.

letter dated securities researcher Li Zhi in the electronics industry in its report that the mobile payment market will spur carriers to step up and banks, CUP, equipment providers, system integrators, business and other cooperation, advance preemption Group users, merchants and end users, mobile payment business experiments will lead to the upstream and downstream industry chain, including chip, card manufacturers, mobile operators, service providers and handset manufacturers,chalswu, including mobile payments value chain.

“as SIM card supplier, Eastcom Peace holds the current China Mobile RF-SIM card market share of nearly 70% of direct benefit significantly; as China Unicom and China Telecom, the communications card supplier, although there is Hublot shares no RF-SIM card orders, but the United Kingdom through the acquisition of the East China Mobile SIM card into the card provider, and with the two telecom operators China Unicom and mobile payment services in the follow-up started, Hublot shares may be directly beneficiaries. “Mr Lee said in his report.

“the next 2 to 3 years, China Mobile plans to businesses, schools, subway, bus and other systems to install one million units in the RF-POS machines, initially forming the initial network construction to 2,000 yuan each machine the market prices, market size 20 million. “Mr Lee said the same time.

Huatai Securities also noted that the Joint South-day information as a priority in the financial sector’s IT service providers in the mobile payment platform solutions, the competition has a certain advantage, the present-day South cooperation has been with the mobile operators in the pilot provinces platform. This year the company expected to maintain 20% market share, POS machine business also will become a new growth point. Maintain their “overweight” rating.

background

mobile payment development path of ups and downs

It is understood that payment of the first mobile phone by sending SMS, visit the Web site such as use of bank card transactions account , only the phone number and bank cards can be bound to pay account. After paying the scene emerged, now in the mobile launch of the “mobile wallet” services including on-site consumption on payment. It is understood that the mobile phone payment service has been launched 6 years, but this has not been plain sailing.

present, China Mobile, “mobile wallet” service used by the program for the RF-SIM, that by replacing the RF-SIM card, no need to change phone numbers, cell phone in the POS machine can be realized, public transportation subway service place, “Brush” consumption. “Now look, RF-SIM program in general is more perfect, the SIM card and phone card the same size, and ultra-high frequency microwave can easily pass through cell phone lithium battery and metal plates, is China’s mobile ‘mobile wallet’ used by business . “letter of the securities on the electronics industry researcher Zhi told reporters that at present the business in Hunan, Chongqing, Guangdong, Shanghai and other provinces and cities in more than 10 trial, expected to use at least 50 million or more people.

with RF-SIM program different field form of payment including NFC and SIM-pass. Mr Lee said, NFC by Philips, Nokia and Sony, the main push, its application is an NFC chip embedded in mobile phones, and SIM card after the Internet. “This model requires users to change phones, due to higher costs, it is difficult to promote; the SIM-pass programs, though not replace the phone, but because of low frequency, the card placed in the signal due to weak batteries or lithium batteries can not pass through metal plates, poor stability of the program in 2006, operators within the trial, there are about less than 5 million users. The two models now almost at a standstill.

> Related: smart card mobile payment business letter start work Department will develop mobile payment standards will be developed micro-Ministry of Industry and Ministry of Industry and mobile payment standard micro preparation standards Zhejiang Telecom mobile payment mobile phone payment pilot, more than 60 commercial contracting business
相关的主题文章：

• 2000 yuan is the kingly quality High Performance C
• Terry Gou, Foxconn and the earthquake area to cont
• Interview with UC Yu Yongfu to achieve fiscal bala

Lead: Foreign media analysis of articles published today, couplet Fake how cottage phone chip supplier for the world’s second-largest growth in mobile phone chip maker, and its future development are analyzed.

The following is the article text:

cost competitive advantage

a little-known Taiwanese chip design company has made waves in the mobile phone market, the company from the United States where large rivals to seize market share, but also reduces the price of mobile phone consumers.

MediaTek’s main business is small for the Chinese mainland handset manufacturers to provide simple, low-cost chip. The company’s chips contributed to China’s “cottage phone” industry’s rapid growth. Fanciful cottage phones, fancy, and often imitate well-known brands of mobile phones, currently occupies 1 / 5 of China’s mobile phone market.

chip business growth to MediaTek’s market share growing, traditionally, the market has been the United States, Qualcomm (Qualcomm), Texas Instruments (Texas Instruments) and Germany’s Infineon ( Infineon Technologies), and other famous firms.

now, MediaTek has been started in the market range par with large companies. Late last year, the company and Motorola co-production of the 7 mobile handsets for the emerging markets, prices are in USD 150. Motorola became the first technology approved MediaTek’s mobile phone giant. This year in February, MediaTek a partnership with Microsoft to jointly produce smart phones for emerging markets.

U.S. market research firm iSuppli Corp. Said that early last year, Texas Instruments, MediaTek beyond the world’s second-largest mobile phone chip maker, and are shorter and ranked first in the high-pass distance; the third quarter of 2009, MediaTek in the global mobile phone chip market share is 24%, while Qualcomm’s share is 37%.

last year, MediaTek’s sales rose 30%, while other businesses also have a high-pass revenue has fallen significantly. MediaTek said the company’s revenue in the first three months of this year grew by 38%, mainly due to China and other emerging markets on strong demand for mobile phone chips. MediaTek Chief Financial Officer Yu Ming Tudor said: “We are confident that the company’s market share will continue to increase.”

MediaTek’s rise shows that in the past to low-cost manufacturing-based R & D capabilities of Taiwan’s technology industry is constantly upgrade, which previously led R & D has been developed. In accordance with the fourth quarter of last year’s shipments basis, Taiwan’s macro? Computer has surpassed Dell as the world’s second-largest PC maker, but the distance is shorter and Hewlett-Packard.

for China mobile phone market

Although MediaTek’s not the best at high-tech innovation, but it will the Taiwan OEM manufacturers of flexible, low-cost advantages of application to the semiconductor design field of micro-chips designed primarily for mobile phones and other electronic products.

Credit Suisse (Credit Suisse) analyst Jessica? Zhang (Jessica Chang) said: “The mobile phone manufacturers are increasingly being MediaTek products attractive because these products feature reliable, low price. “

founded in 1997, MediaTek chips through the production of cheap DVD machine started, but also so that once the high price of DVD machines become a common consumer products. The company began six years ago involved in mobile phone chip industry, mainly for the Chinese market, China currently has a 757 million mobile phone users.

phones use a variety of different chips. Typically, the mobile phone manufacturers to buy chips and then assembled, respectively, while the MediaTek chipset provides the majority of components, including mobile phones, mobile phone manufacturers to facilitate the development of new products. Some analysts estimate that MediaTek chipset to reduce handset development time in half, reduce the cost by 25% to 50%.

MediaTek chip for the cottage brought benefits to handset manufacturers. Diverse range of products these companies, including imitation of Nokia mobile phones,I Can Fly, built-in razor cell phone, palm-sized “mini iPhone\

While theft of intellectual property rights as well-known manufacturers have been scoffed, but such a large number of companies have emerged in recent years in China, while also promoting a MediaTek’s sales growth.

In addition, MediaTek has also sent engineers to help more Chinese enterprises to carry out research and development. For example, in MediaTek’s help, including the day of languages, including well-known mobile phone manufacturer’s market share has grown.

days Xu Kun language brand manager, said: “We MediaTek as their teachers, they provide not simply a series of technical, but the entire production process.”

Yu-ming, said Murdoch, MediaTek also help customers in mainland China for the development of other emerging markets mobile phones, including the Indian farmers developed large volume mobile phone so that they work in the paddy fields can hear the bell; along with Islamic countries The mobile phone with electronic compass,update my life, the compass will point to the direction of Mecca.

into 3G area

BNP Paribas Securities (BNP Paribas Securities) said that the current use of chip manufacturers in China, half is provided by a MediaTek, the mainland market MediaTek chips provide 90% of revenue. In the past five years, MediaTek’s average annual growth rate of 24%. Last year, MediaTek’s sales reached 3.6 billion U.S. dollars, net profit rose 91% to 1.2 billion U.S. dollars.

MediaTek challenge is to the success of past transplanted to 3G, because the share of China’s 3G mobile phones is growing. In 2007,好好学习, MediaTek acquisition of the U.S. Analog Devices Inc., one of the reasons the company has helped China develop TD-SCDMA technology, which is currently used by China Mobile.

MediaTek’s biggest competitors have to commend his. Qualcomm CDMA Technologies Eddie Chang, vice president of sales, said: “MediaTek is a worthy opponent.” As the world’s largest mobile phone chip maker Qualcomm controls the majority of 3G in the field of intellectual property rights, and tries to emerging markets provide low-cost products. Last year, MediaTek, and high accessibility became a “broad patent agreement\

However, analysts believe, MediaTek and Qualcomm, and other cell phone chip business competition will intensify. IDC’s wireless semiconductor analyst at Flint? Pasikapu (Flint Pulskamp) said: “MediaTek other cell phone chip business will be in direct competition, I think, they have prepared for this.” (Liang Qin)

> Related: MediaTek chairman Cai Ming Kai: CEO of the most important four things MediaTek chips for ZTE to provide products TD Wang Taiwan’s MediaTek shares to 5.62 billion with interest
相关的主题文章：

• The wide dissemination of CMMB 5 月 1 from the fir
• 2000 yuan is the kingly quality High Performance C
• The wide dissemination of CMMB 5 月 1 from the fir

International Food Policy Research Institute (IFPRI) Staff
Pressroom
Careers
Contact Us
RSS EnglishDeutschEspa?ol Fran?ais Our Work
Our Products
Resources
Countries
News & Events All contentResourcesPressroomDatasetsPublicationsStaffNews & EventsOur Work World Water Day IFPRI celebrates World Water Day with the release of a new book Weather securities proposal among MIF winners “Using Simple Weather Securities to Insure Rain-Dependent Farmers in Ethiopia” among … New DSG Division Director Professor Margaret McMillan will be the director of IFPRI’s Development Strategy and … Prev
1 of 2
Next Research Global Food and Natural Resources Pathways from Poverty Globalization and Markets HarvestPlus Water Resource Allocation Diet Quality and Health of the Poor CAPRi Food and Water Safety Governance and Policy Processes HIV/AIDS and Food Security Rebuilding after Emergencies and Crises Genetic Resource Policies for the Poor Large-Scale Interventions to Enhance Human Capital 2020 Vision for Food, Agriculture, and the Environment Country Development Strategy Climate Change Food Prices Gender

See all research

IFPRI Mailing List Signup for our email list Audience For Researchers
For Policy Professionals
For New Users Featured Publications Innovations in Insuring the Poor January 2010 2020 Focus Social accounting matrices and multiplier analysis December 2009 Food Security in Practice Technical Guide Series Climate change: Impact on agriculture and costs of adaptation September 2009 Food Policy Reports New at IFPRI Event Apr 8, 2010 The New Politics of Food & Farming Event Apr 7, 2010 Alleviating the worst of poverty with water, resilience and innovation News Mar 22, 2010 Margaret McMillan to be Director of the Development Strategy and Governance Division News Mar 22, 2010 IFPRI celebrates World Water Day with the release of a new book Press Release Mar 22, 2010 Fostering Growth,Tiffany Jewelry, Reducing Poverty and Hunger Event Mar 22, 2010 Fostering Growth and Reducing Poverty and Hunger in Asia and Latin America Staff
Pressroom
Careers
Contact Us
RSS Our Work
Our Products
Resources
Countries
News & Events © Copyright and Fair Use
IFPRI is supported by the Consultative Group on International Agricultural Research (CGIAR)
             &nbsp,Louis Vuitton;   Phone +1 202-862-5600
Fax +1 202-467-4439
Email ifpri@cgiar.org Skypeifprihomeoffice International Food Policy Research Institute
2033 K St, NW
Washington,UGG Boots, DC 20006-1002 USA
相关的主题文章：

• Shark Research Institute- shark conservation, educ
• Telcordia – telecom oss, service delivery, interco
• Research Institute for the Humanities – Philosophy

http://www.ust.hk/eng/index.htm ,gucci bags
HKUST&nbsp,prom dresses; |  Contact Us&nbsp,gucci;    Designed by Publishing Technology Center Copyright © 2008 HKUST. All Rights Reserved
相关的主题文章：

• Forrester Blogs
• LAW RESEARCH DEMONSTRATION HOMEPAGE – The Largest
• ROI Reports, ROI Case Studies, ROI Tools Nucleus

R&D Medicines Menu MDMA for PTSD LSD/Psilocybin for Anxiety Related to Life-threatening Illness Ibogaine for Drug Addiction Medical Marijuana Psychedelic Research Around the World Featured Material Are Psychedelic Drug Treatments Seeing a Comeback in Psychology? The Pharmacology of LSD, a Review NewScientist: ?Ecstasy?s Long term Effects Revealed?
Psychedelic Psychotherapy and Spirituality: The Ten Lessons of Psychedelics, Rediscovered. By Neal M. Goldsmith, PhD Features Enter Your Email Address: MAPS Email News Archive   R&D Medicines > Psychedelic Research Around the World.

On this page we have posted information about psychedelic research around the world that is not conducted by MAPS. Our current studies are found on the other pages in the R&D Medicines section.

The studies listed here are limited to those in which psychedelics are administered to human subjects. Studies that focus on comparing psychedelic drug users to non-users of drugs are generally not included, nor are animal studies.

For comprehensive bibliographies of past psychedelic research, including all therapeutic studies as well as other human and animal studies, see our bibliography section.

This page is updated by Ilsa Jerome, Ph.D. If you have any questions, more recent information about any of these studies, or would like to alert us to relevant studies not included here, please write to Ilsa Jerome PhD.

MDMA Research MDMA Studies: In Progress

See also the MDMA Research Page for more links.

MDMA Dose Response Study in Cancer Patients with Anxiety
Investigators: John Halpern MD, Harvard Medical School and McLean Hospital, Belmont MA
Contact:
Sponsor: Peter Lewis
Study of MDMA-assisted psychotherapy in subjects with anxiety as a result of advanced stage cancer, with outcome measures to evaluate anxiety, pain and quality of life. On February 23, 2004, MAPS donated $11,000 to McLean Hospital, Harvard Medical School, for Dr. Halpern’s work on the protocol design and approval process ($15,000 was also donated to McLean for this study on June 2003). MAPS had initially worked with Dr. Charles Grob in a much earlier effort to conduct MDMA research in cancer patients prior to Dr. Grob’s switching to psilocybin (see entry below). For more information about Dr. Grob’s effort. see the details and reference page, the 1995 version of the protocol, and view the video. As of January, 2005, Dr. Halpern’s study has now been approved by the McLean Hospital and Lahey Clinic IRBs, and the FDA has given permission (approved) the study as well. On March 7, 2006, the DEA has approved this study. MAPS has since withdrawn financial support for this study but will continue to assist in seeking donors to help support this study. The first subject has undergone both experimental sessions and had anxiety symptoms evaluated afterwards.
Last updated: Wed Jul 9 2008

Study protocol submitted to IRBs.
Informed consent forms for the study.

Physiological correlates of PTSD before and after MDMA-assisted psychotherapy
Investigators: Dominique Holstein MS
Location: University Psychiatric Hospital, Zurich, Switzerland
Sponsor: HMF Zurich, HRC Zurich
Contact: ,
This study is taking place in conjunction with a randomized, double-blind comparison of low versus experimental doses of MDMA in 12 people with treatment-resisted PTSD, with eight people receiving 125 mg followed by 62.5 mg MDMA, and four people receiving 25 mg followed by 12.5 mg MDMA being conducted by Peter Oehen MD. Dr. Oehen’s study offers a unique opportunity to investigate further possible links between changes in physiological measures associated with the symptomatology of PTSD and improvement in patients undergoing treatment and symptom relief. People with PTSD may have deficits in information processing such as failures in sensory gating or filtering out information. Such measures of inhibition failure include prepulse inhibition (PPI) of the acoustic startle reflex and P50 auditory evoked potential suppression. Measures of impaired cognitive performance include various types of evoked response potential (EEG-ERP). Psychophysiological measures include skin conductance and heart rate variability. Differences in these measures are associated with having PTSD, but they have never been measured in the same individuals as part of a single investigation before. Thus the aim of the present longitudinal study is 1) to characterize PTSD patients using a broad range of physiological candidate measures (PPI, P50, SC, HRV) and cognitive paradigms (P200, P300), and second, to investigate how these measures relate to the symptomatology of PTSD and clinical outcome.
All PTSD patients that participate in Dr. Oehens study of MDMA-assisted psychotherapy will be assessed at baseline, before undergoing MDMA-assisted psychotherapy, and three weeks after the third MDMA-assisted session. On the long run, the assessment of multiple physiological measures in PTSD patients shall further our understanding of the pathophysiology of this illness and increases the possibility to identify subgroups of PTSD patients, and help to identify more specific treatments.
Last updated: Tue Aug 28 2007

 

MDMA Studies: Under Development

See also the MDMA Research Page for more links.

 

MDMA Studies: Completed

Serotonin and Dopamine system interactions in the reinforcing properties of psychostimulants
Investigators: Manny Tancer, MD and Charles Schuster, PhD
Wayne State University – Detroit, Michigan, USA
Contact:
Sponsor: NIDA
Psychobiological studies approved and in process. An MDMA dose-response study and a comparison of MDMA, d-amphetamine and mCPP are completed. The first paper about this research was published in December, 2001, and a second report was published in November 2003.
Last updated: Thu Feb 2 2006

Tancer M, Johanson CE. (2006) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) Published online Oct 18; Freedman RR, Johanson CE, Tancer ME. (2005)Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.Psychopharmacology (Berl). 2005 183(2):248-256.
Johanson CE, Kilbey M, Gatchalian K, Tancer M. (2005) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend. 2005 Published On-line June 20. Tancer ME, Johanson CE (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d-amphetamine and mCPP.
Drug and Alcohol Dependence 72: 33-44.
Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users.
Drug Alcohol Depend. 2001 Dec 1;65(1):97-101.
Serotonin and dopamine system interactions in the reinforcing properties of psychostimulants. MAPS – Volume 7, Number 3; Summer 1997.

Behavioral Effects of MDMA Related to Driving Ability
Investigators: C.T.J. Lamers PhD, J.G. Ramaekers PhD, W.J. Riedel
University of Maastricht, the Netherlands
Contact:
Sponsor: Ministry of Transport, the Netherlands
This research examines MDMA effects on driving related task performance, including psychomotor function
(such as tracking, movement speed), cognitive function (attention, executive
function and planning) and object movement prediction. In addition, mood
changes and physiological measures were assessed, and MDMA levels were measured in blood,
sweat, urine and saliva. Studies already published were conducted according
to a placebo-controlled, cross-over, double-blind design and treatments
included placebo, 75 mg MDMA and 0.5 g/kg alcohol.
Last updated: Wed Apr 7 2004

Brookhuis KA, De Waard D, Samyn N. (2004) Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology (Berl). 2004 Jan 9 [Epub ahead of print] Lamers CT, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ. (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol. 17(4):379-387. Samyn N, De Boeck G, Wood M, Lamers C, De Waard D, Brookhuis K, Verstraete A, Riedel W (2002) Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128: 90-97.

Effects of MDMA (”Ecstasy”) on the Human Brain
Investigators: Franz Vollenweider, MD, Alex Gamma, PhD
Psychiatric University Hospital – Zrich, Switzerland
Contact: //–> and
Sponsors: Swiss National Science Foundation, UBS Science Foundation
Psychobiologic studies including: assessment of possible
neurophysiological, psychological and cognitive alterations in chronic
MDMA users; evaluation of the role of serotonin, dopamine and
norepinephrine systems in mediating the effect of MDMA on mood,
psychomotor behavior and sensorimotor gating in humans, investigating
whether regular MDMA users show alterations in 5-HT reuptake site
densities indicative of neurotoxic effects after long-term MDMA use.
MAPS donated $6,000 to a sub-study in which 10 MDMA-naive subjects will
receive a PET scan to measure serotonin reuptake sites before and after
a single dose of MDMA (1.5-1.7mg/kg)

Last updated: Mon Jun 18 2001

For details see the MDMA Research in Switzerland Page

Gender Differences in the Subjective Effects of MDMA
Investigators: Liechti ME, Gamma A, Vollenweider, FX
Sponsors/Funding: Swiss National Science Foundation; Swiss Federal Health
Office; Heffter Research Institute
References: Psychopharmacology DOI (2001) 10.1007/s002130000648

Last updated: Fri Feb 16 2001

Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans After Pretreatment with Citalopram, Halperidol, or Ketanserin
Investigators: Liechti ME, Geyer MA, Hell D, Vollenweider FX
Sonsors/Funding: Swiss National Science Foundation; Swiss Federal Health
Office; Heffter Research Institute
References: Neuropsychopharmacology (2001) 24:240-252

Last updated: Fri Feb 16 2001

MDMA Pharmacokinetics and Pharmacodynamics in Humans
Investigators: John Mendelson, MD and Reese Jones, MD
UC San Francisco – California, USA
Contact person:
Sponsor: NIDA
Drug administration phase completed, eight subjects were given 0.5 and
1.5 mg/kg MDMA HCl. A paper from it is in press at Annals of Internal
Medicine. Data was presented at two
conferences.

Last updated: Mon Sep 18 2000

See also Research in Germany.
See the MDMA Research Page for more links.

Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl) 162: 396-405.
Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 133: 969-973.

Clinical pharmacology of the interaction between alcohol and MDMA
Investigators: Jordi Cam, MD, Magi Farr, MD, et al.
Institut Municipal d’Investigacio Medica – Barcelona, Spain
Contact:
Sponsor: funded in part by several government grants
Psychobiologic study looking at the interaction of MDMA (100 mg) and alcohol (.8 g/kg). Analysis nearly completed, papers being written. See the current update.

Last updated: Thu Sep 14 2000

Mood state and brain electric activity in Ecstasy users
Investigators: Alex Gamma, PhD, Edi Frei, Dietrich Lehmann (1), Roberto D. Pascual-Marqui (1), Daniel Hell and Franz Vollenweider, MD
Research Unit and (1) The KEY Institute for Brain-Mind Research, University Hospital of Psychiatry, Zrich
Sponsors/Funding: Swiss National Science Foundation; Swiss Federal Health
Office; Heffter; MAPS.
Contact:
References Neuroreport (2000) 11 (1): 157-162.

Last updated: Wed Feb 9 2000

Pharmacological Effects of MDMA in Humans
Investigator: Jordi Cam, MD, Magi Farr, MD, et al.
Institut Municipal d’Investigacio Medica – Barcelona, Spain
Contact: or
Sponsor: funded in part by several government grants
Studies include: Quantification of MDMA and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection; Human pharmacology of MDMA, Psychomotor performance and subjective effects.
Also see a list of published papers.

Last updated: Mon Jan 24 2000

Psychobiologic Effects of MDMA in Humans
Investigators: Charles S. Grob, MD, and Russell E. Poland, PhD
Harbor-UCLA Medical Center – Torrance, California, USA
Sponsor: MAPS, Harbor/UCLA
Contact: ,
FDA-approved Phase 1 dose-response safety study .25 to 2.25 mg/kg, dose administration phase completed, data for .25 to .75 mg/kg published. Data for 1.00 to 2.25 mg/kg being analysed for publication.

Also see the details and references page, and view the video.

Last updated: Wed Jan 19 2000

Acute effects of 3, 4 – methylenedioxymethamphetamine (MDMA; “Ecstasy”) on cerebral blood flow (CBF), brain electric activity (EEG), prepulse inhibition (PPI), psychological state and neuropsychological performance in healthy subjects
Investigators: Alex Gamma, PhD, Franz Vollenweider, MD
Psychiatric University Hospital – Zrich, Switzerland
Sponsor: UBS Science Foundation and others
Contact: or
Aim: an integrative characterization of MDMA in terms of its acute
neurophysiological, psychological and cognitive effects in healthy,
MDMA-naive human subjects. Subjects were given a single oral dose of
MDMA (1.7 mg/kg).
Also see the references and details page.
Last updated: Tue Jan 18 2000

Low-dose MDMA (”Ecstasy”) induces vasopressin secretion
Investigator: John Henry, MD
University College London, England
Contact:
This was a neurotoxicity study. Henry is directing additional MDMA studies at this time.

Last updated: Fri Jan 14 2000 Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ.
Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy)
in humans.
Clin Chem 1999 Jul;45(7):1058-69. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M
Low-dose MDMA (”ecstasy”) induces vasopressin secretion.
Lancet 1998 Jun 13;351(9118):1784.

Psycholytic Therapy with MDMA and LSD in Switzerland
Investigators: Marianne Bloch, MD, Jurai Styk, MD and Dr. Samuel Widmer, MD
Sponsor: Swiss Medical Society for Psycholytic Therapy
From 1988 to 1993 therapists with the Swiss Medical Society for Psycholytic
Therapy worked with MDMA and LSD as adjuncts to psychotherapy. The findings
from this study were published in the
MAPS Bulletin, Winter 1994-95 issue.

Drs. Juraj and
Sonja Styk discussed this work at the 1999 MAPS MDMA symposium in Israel.

Read their talk, and view a video

Last updated: Fri Jan 14 2000

MDMA (Ecstasy): Does It Play A Causal Role In Nephropathy? A Review
John Podraza, Department of Biological Sciences, Hartwick College, New York

Level of use of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) in humans correlates with EEG power and coherence
Investigators: Dafters RI, Duffy F, O’Donnell P, Bouquet C
Psychology Department, Glasgow University, Glasgow, Scotland G12 8RT
Sponsor(s)/Funding: Self funded
Contact: N/A
References: Psychopharmacology (1999) 145: 82-90, Abstract.

Last updated: Tue Jul 13 1999

MDMA and Memory
Investigators: Karen Bolla, PhD et al.
Johns Hopkins University – Baltimore, Maryland
Sponsor: NIH
Neuropsychological memory testing of MDMA users and controls.

Last updated: Fri Apr 9 1999

Also see Alex Gamma – MDMA and Memory

Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA (”Ecstasy”) users. Neurology Dec 1998;51(6):1532-7.
U D McCann, Z Szabo, U Scheffel, R F Dannals, G A Ricaurte (1998) Positron emission tomographic evidence of toxic effect of MDMA (”Ecstasy”) on brain serotonin neurons in human beings. The Lancet Oct 1998; 352(9138): 1433-37.

MDMA Pharmacokinetics
Investigator: Rudolf Brenneisen, PhD
University of Bern, Switzerland
Contact: br>
Completed and published, just a few subjects.
Also see the details and references section.

MDMA Neurotoxicity Study
Investigators: Una McCann, MD, George Ricaurte, MD, PhD
Johns Hopkins University – Baltimore, Maryland
Contact:
Sponsor:NIH
PET scan study, MDMA Neurotoxicity, MDMA Users vs. Control Group.

MAPS Commentary on this study MDMA Neurotoxicity Study Page from Vaults of Erowid

 

MDE Research MDE Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

MDE Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

MDE Studies: Completed

See also Research in Germany

The Psychological, Neuroendocrine, Cardiovascular and Sleep-EEG Effects of MDE
Investigators: Euphrosyne Gouzoulis-Mayfrank, MD et al.
Aachen, Germany
Contact: Sponsor: DFG (Deutsche Forschungsgemeinschaft = German Research Foundation)
Human research on neurobiological and subjective effects of MDE. References and details.

Last updated: Tue Feb 18 2003 Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H,
Spitzer M. (2002) Effects of the
hallucinogen psilocybin on covert orienting of visual attention in humans.
Neuropsychobiology, 45:205-212. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4- methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565-81. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142: 41-50. Schreckenberger M, Gouzoulis-Mayfrank E, Sabri O, Arning C, Zimny M, Zeggel T, Wagenknecht G, Kaiser HJ, Sass H, Buell U (1999) “Ecstasy”-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study. Eur J Nucl Med 26: 1572-9. Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M, Kovar K, Hermle L, Gron G (2001) Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 41: 263-71.

Differential Cognitive and Brain Activation Effects of the Isomers of MDE
Investigators: Dr. Spitzer, et al.
University of Ulm, Germany
Contact:
This study was a double-blind, placebo-controlled investigation of the cognitive and brain activation effects of the isomers of MDE. The researchers concluded “The so-called entactogenic effects of MDE are likely to be caused by the (S)-enantiomer, whereas (R)-MDE appears to be responsible for neurotoxic effect.”
Last updated: Tue Jan 29 2002 Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M, Kovar K, Hermle L, Gron G (2001) Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 41: 263-71.

Ayahuasca Research Ayahuasca Studies: In Progress

Exploring Personality, Phenomenological, and EEG Correlates of the Ayahuasca Journey Experience to Facilitate an Individual
Investigators: Frank G. Echenhofer Ph.D., Katee Wynia MA, Jay Gunkelman QEEGD, Luis Eduardo Luna Ph.D., Wayne G. Whitehouse Ph.D, California Institute of Integral Studies, San Francisco CA.
Sponsor: Currently self-funded; MAPS providing publicity and serving as conduit for tax-deductable donations.
Contact:
The purpose of this proposed research is to further study the patterning and dynamics of enhanced EEG gamma coherence during ayahuasca to develop biofeedback protocols, which, in turn, might be used to enable individuals to voluntarily access states of heightened awareness without using an entheogen. Previous EEG recordings from two individuals very familiar with the sacred use of ayahuasca detected high gamma EEG. The current research is designed to replicate and extend these earlier findings, and will be conducted in twelve research participants familiar with the sacred use of ayahuasca who will take part in an ayahuasca seminar occurring in southern Brazil from January 7-18, 2005 designed to facilitate spiritual development.

Potential research participants and donors can view the research proposal for this study. Those interested in making a donation can read more about how to do this.
Last updated: Thu Mar 5 2009

Read Dr. Echenhofer’s research proposal.

The therapeutic potential of substance abuse treatment with Ayahuasca-a qualitative study
Investigator:Dipl. Psych Anya Loizaga-Velder, University of Heidelberg, Germany
Contact:
This qualitative study will involve interviewing 10 health professionals who work with ayahuasca as an adjunct for substance abuse treatment in order to gain a deeper understanding about the therapeutic process of ayahuasca-assisted therapy for addiction, as well as identifying major differences in conceptualization and practice of the addiction treatments. Loizaga-Velder will also interview five health professionals who are working or have worked with other psychedelics as adjuncts to treatment of addiction. A follow up study of 10 subjects who have participated in ayahuasca intervention for addiction will also be conducted. The research seeks to examine how ayahuasca is used in different contexts of addiction treatment and the institutional, psychological and social conditions that provide for a successful treatment outcome for ayahuasca-assisted therapy for addiction. This research is part of the Ritual Dynamics and Salutogenesis project ( RISA); www.risa.uni-hd.de.
Last updated: Fri Jan 18 2008

Pharmacological, imaging and immunological studies of Ayahuasca in Healthy Volunteers
Investigators: Manel Barbanoj, MD, PhD and Jordi Riba
Institute de Recerca, Hospital de Sant Pau – Barcelona, Spain
Sponsor: Institut de Reserca, Hospital de la Santa Creu i Sant Pau (HSCSP)
Contact:
A study of the urinary excretion of ayahuasca alkaloids in the 22-volunteer, double-blind study (described below) is planned
but has not yet been conducted due to lack of funding. The double-blind brain-imaging study using SPECT to study regional cerebral blood flow after ayahuasca administration has been fully approved and is now in progress. As of this date, seventeen volunteers have undergone all experimental sessions. This study will also look for any immunomodulating effects of ayahuasca. These studies are seeking additional information on mechanisms of action underlying the central effects of ayahuasca.
Read the update in the MAPS Bulletin, Summer 2000 issue.

Last updated: Mon Feb 23 2004

“A Pharmacological Study of Ayahuasca in Healthy Volunteers” – Jordi Riba and
Manuel J. Barbanoj, M.D., Ph.D., MAPS Bulletin, Vol. 8 No. 3, Autumn 1998

Ayahuasca Studies: Under Development

Long Term Outcomes Of Substance Abuse Treatment At Takiwasi Center
Investigators: Anne Denys, Rosa Giove, Fernando Mendive.
Takiwasi Center – Tarapoto, Peru
Contact:
Sponsor: not yet funded
For fifteen years, Takiwasi Center has offered an innovative substance abuse treatment. It is based on a therapeutic model that harmoniously integrates selected interventions from modern psychology and medicine, with key concepts and healing techniques from traditional Amazonian medicine. In this model, Ayahuasca plays a central role in the therapeutic process. The present study will evaluate the outcomes on ex-patients discharged from Takiwasi Center for more than five years prior to assessment and meeting the highest standards in the field of addiction research.
Giove R. (2002) Medicina Tradicional Amaznica en el tratamiento de las toxicomanias. La Liana de los muertos al rescate de la vida. 7 aos de experiencia del centro Takiwasi. Comision Nacional para el Desarrollo y Vida sin Drogas, DEVIDA, Takiwasi, Centro de Rehabilitacin de Toxicmanos y de Investigacin de las Medicinas Tradicionales [Book published by Takiwasi Center].

Pharmacological Study of Ayahuasca in Healthy Humans
Investigators: Manel Barbanoj, MD, PhD and Jordi Riba
Institute de Recerca, Hospital de Sant Pau – Barcelona, Spain
Sponsor: Institut de Reserca, Hospital de la Santa Creu i Sant Pau (HSCSP), partial funding from Spanish government.
Contact:
A repeated dose study and a neurochemical mechanism study designed to evaluate the capacity of 5HT1A agonists and 5HT2A antagonists to block the effects of ayahuasca will both be conducted soon. These studies are also included as part of the program of research including a SPECT study of regional blood flow after ayahuasca that is already in progress, as described above.

Last updated: Fri Feb 20 2004

Ayahuasca Studies: Completed

Ayahuasca in the Treatment of Substance Abuse
Investigators: Jacques Mabit, Jaime Torres, Rosa Giove, Javier Zavala, Olga Celis
Takiwasi Center – Tarapoto, Peru
Contact:
Website: www.takiwasi.com
Sponsors: Self-financed, funding sought from the French government, European Union, and United Nations
Takiwasi has been doing research with substance abuse treatment for several years.

Last updated: Wed Mar 4 2009

Mabit J, Sieber C (2006) The Evolution of a Pilot Drug Treatment Program Using Ayahuasca. Shamans Drum Journal 73: 23-31 Mabit, J (2007) Ayahuasca in the treatment of addiction. Chapter 6; In Hallucinogens and Health : New Evidence for Psychedelic Substances as Treatment (Vol 2) Ed. MJ. Winkelman & TB. Roberts; Greenwood Publishing Group; pp 87-105.
“Itinerary and Testimony of Dr. Jacques Mabit, physician and shaman, a conversation with Frederique Appfel-Marglin, in INTERculture, Journal of the Intercultural Institute of Montreal, Issue No. 152, Identity and Religious Pluralism, Montral, Canada, April 2007. “Blending Traditions – Using Indigenous Medicinal Knowledge to Treat Drug Addiction” – Jacques Mabit, M.D., MAPS Bulletin, Vol. 12 No. 2, Summer 2002. [PDF version] “Ayahuasca and Shamanism in Addiction Therapy” – Michel Mabit, MAPS Bulletin, Vol. 6 No. 3, Summer 1996 “The Takiwasi Patient’s Journey” – Michel Mabit, MAPS Bulletin, Vol. 6 No. 3., Summer 1996

A Study of Uniao do Vegetal (UDV) Adolescents
Investigators: Charles Grob, MD, Ailonso Luiza, Claudia Miranda,
Glacus de Souza Brito, MD and Marlene de Rios
Sao Paulo, Brazil
Contact:
Sponsor: Heffter
Testing and evaluation of adolescents who have used ayahuasca and matched controls have been completed. Data review now in process.

Last updated: Thu Feb 26 2009 Dobkin de Rios, M.. and Grob, CS (2005) Ayahuasca use in cross-cultural perspective: an introduction. Journal of Psychoactive Drugs 37:119-121. Doering-Silveira, E, Grob, CS, Dobkin de Rios, M, Lopez, E, Alonso, LB, Tacla, C, Brito, GS, Castello, O. and Da Silveira, DX (2005) Ayahuasca in adolescence: a neuropsychological assessment. Journal of Psychoactive Drugs 37:123-128. Doering-Silveira, E, Grob, CS, Dobkin de Rios, M, Lopez, E, Alonso, LB, Tacla, C, Brito, GS, Castello, O. and Da Silveira, DX (2005) Ayahuasca in adolescence: a preliminary psychiatric assessment. Journal of Psychoactive Drugs 37:129-133. Doering-Silveira, E, Grob, CS, Dobkin de Rios, M, Lopez, E, Alonso, LB, Tacla, C, Brito, GS, Castello, O, and Da Silveira, DX (2005) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. Journal of Psychoactive Drugs 37:135-139. Dobkin de Rios, M, Grob, CS, Loopez, E, Da Silveira, DX, Alonso, L. and Doering-Silveira, E. (2005) Ayahuasca in adolescence: qualitative results. Journal of Psychoactive Drugs 37:141-144.

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members
Investigator: Rafael G. dos Santos
Departamento de Processos Psicologicos Basicos, Instituto de Psicologia, Universidade de Brasilia, Brasilia-DF, Brazil
Current address: Institute de Recerca, Hospital de Sant Pau,UGG Boots, Barcelona, Spain
Sponsor: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Contact:

The use of the hallucinogenic brew ayahuasca, obtained from infusing the shredded stalk of the malpighiaceous plant Banisteriopsis caapi with the leaves of other plants such as Psychotria viridis, is growing in urban centers of Europe, South and North America in the last several decades. Despite this diffusion, little is known about its effects on emotional states. The present study investigated the effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in members of the Santo Daime, an ayahuasca-using religion. Standard questionnaires were used to evaluate state-anxiety (STAI-state), trait-anxiety (STAI-trait), panic-like (ASI-R) and hopelessness (BHS) in participants that ingested ayahuasca for at least 10 consecutive years. The study was done in the Santo Daime church, where the questionnaires were administered 1 h after the ingestion of the brew, in a double-blind, placebo-controlled procedure. While under the acute effects of ayahuasca, participants scored lower on the scales for panic and hopelessness related states. Ayahuasca ingestion did not modify state or trait anxiety. The results are discussed in terms of the possible use of ayahuasca in alleviating signs of hopelessness and panic-like related symptoms.
Last updated: Fri Jan 23 2009 Santos RG, Landeira-Fernandez J, Strassman RJ, Motta, V, Cruz APM Effects of Ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology 112 (3): 507-513. 2007. .
Santos RG. Ayahuasca: Neuroquimica e Farmacologia. SMAD – Revista Eletronica Saude Mental Alcool e Drogas, 3 (1), 2007.
Santos RG. “Efeitos da ingestao de ayahuasca em estados psicometricos relacionados ao panico, ansiedade e depressao em membros do culto do Santo Daime”. Nucleo de Estudos Interdisciplinares sobre Psicoativos NEIP, 2006.
Santos RG “Ayahuasca e reducao do uso abusivo de psicoativos: eficacia terapeutica?”. Nucleo de Estudos Interdisciplinares sobre Psicoativos NEIP, 2006.
Santos, RG, Moraes, CC. and Holanda, A. Ayahuasca e reducao do uso abusivo de psicoativos: eficacia terapeutica?. Psicologia: Teoria e Pesquisa, 22 (3): 363-370. 2006. More references at http://www.neip.info/index.php/content/view/83.html

MMPI-2 Study of N.A. Ayahuasca Drinkers
Here are the docs for this study figures and document

Pharmacological Study of Ayahuasca in Healthy Volunteers
Investigators: Manel Barbanoj, MD, PhD and Jordi Riba
Institute de Recerca, Hospital de Sant Pau – Barcelona, Spain
Sponsor: Institut de Reserca, Hospital de la Santa Creu i Sant Pau (HSCSP)
Contact:
The initial pilot study has been completed, including a published report of subjective effects in 6 volunteers. An 18-subject, double-blind, placebo-controlled study of ayahuasca effects is now complete. Included were measures
of subjective effects, cardiovascular effects, sensorimotor gating, EEG variables, urinary monoamine metabolite excretion, and pharmacokinetics of ayahuasca alkaloids.
Last updated: Fri May 9 2003 Riba J (2003) Human Pharmacology of Ayahuasca, TESI Doctoral Dissertation, Universitat Autonoma de Barcelona. Riba J, Valle M, Urban G, Yritia M, Morte A, Barbanoj MJ (2003) Human Pharmacology of Ayahuasca: Subjective and cardiovascular effects, monoamine metabolite exretion, and Pharmacokinetics. JPET 306 (In Press) Riba, J et al. (2001) Subjective Effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology 154:85-95. Riba J, Rodriguez-Fornells A, Barbanoj M (2002) Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl), 165: 18-28 Riba J, Anderer P, Morte A, Urbano G, Jane F, Saletu B, Barbanoj M (2002) Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Brit J Clin Pharmacol 53: 613-628 Yritia M, Riba J, Ortuno J, Ramirez A, Castillo A, Alfaro Y, de la Torre R, & Barbanoj MJ(2002): Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca Journal of Chromatography B 779:271-281 “A Pharmacological Study of Ayahuasca in Healthy Volunteers” – MAPS Bulletin, Vol. 8 No. 3, Autumn 1998

EEG of Long-Term Ayahuasca Drinkers vs. Matched Controls
Investigators: Dr. Micheal Hessellink (Holland), Yatra da Silveira Barbosa (Brazil), Dr. Erik Hofmann (Denmark). Co-investigators are: Dr. Glacos
Brito and Dr. Dartiu Xavier da Silveira both from Brazil.
Sao Paulo, Brazil
Contact:
The protocol has been completed and an article reporting on the results is published in the MAPS Bulletin, Spring 2001.

Last updated: Wed Mar 5 2003 Hoffmann E, Hesselink JMK, da Silveira-Barbosa YWM. Effects of a Psychedelic, Tropical Tea, Ayahuasca, on the Electroencephalographic (EEG) Activity of the Human Brain During a Shamanistic Ritual.
MAPS Bulletin 2001 Spring;11(1):25-31. [PDF version]

Investigations on the Human Psychopharmacology of Ayahuasca: Phase I
Investigators: Dennis J. McKenna, PhD and Charles S. Grob, MD and Jace Callaway, PhD
Contact: and
Sponsor: Botanical Dimensions, Heffter, MAPS
Psychobiologic study, completed and published, follow-up studies possible.

Last updated: Mon Mar 3 2003

“Blending Traditions – Using Indigenous Medicinal Knowledge to Treat Drug Addiction” – Jacques Mabit, M.D., MAPS Bulletin, Vol. 12 No. 2, Summer 2002. [PDF version] “Jungle Pilgrims: North Americans Participating in Amazon Ayahuasca Ceremonies” – Kim Kristensen References and links to additional articles

DMT Research DMT Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

DMT Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

DMT Studies: Completed

Human Psychopharmacology of N,N-dimethyltryptamine
Investigator: Rick Strassman, MD
University of New Mexico, USA
Contact:
Sponsor: NIDA
Psychobiological study, finished and published.
Last updated: Fri Apr 9 1999

MAPS Bulletin – Volume 6 Number 1 Autumn 1995
University of New Mexico Update

Ibogaine Research Ibogaine Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to Ilsa Jerome PhD. Please also visit our ibogaine page.

Ibogaine Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Ibogaine Studies: Completed

There is additional information about ibogaine research at www.ibogaine.org

Ibogaine treatment study with addiction
Investigator: Deborah Mash, PhD
St. Kitt, Virgin Islands
Contact:
Sponsor: Healing Visions Institute for Addiction Recovery, Ltd.
Sponsor: Healing Visions Institute for Addiction Recovery, Ltd.
Clinical study of the safety and efficacy of ibogaine in the treatment of addiction, with data gathered from patients treated by Dr. Mash, an expert in the study of ibogaine in human patient volunteers. To date, she has evaluated the effect of ibogaine in over three hundred patients. Due to a lack of funds, most of these data come from treatment conducted off-shore. This study is now completed, and Dr. Mash submitted data to FDA in 2007.

Last updated: Thu Mar 5 2009 Mash, D.C., Kovera, C.A. Pablo, J., Tyndale, R. F., Ervin, F.D., Williams,Tiffany Jewelry,
I.C., Singleton, E.G., and Mayor, M.
Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary
Efficacy. Neurobiological Mechansisms of Drugs of Abuse, Annals New York Acad. Sci. Vol. 94: 394-401, 2000.
Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J, (1998)
Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependence, Annals NY Acad Sci, v 844 pp 274-292.

Safety studies in preparation for proposed study of ibogaine therapy in the treatment of cocaine addiction
Investigators: Juan Sanchez-Ramos, MD, PhD and Deborah Mash, PhD
Unversity of Miami Medical School – Florida, USA
Contact:
Sponsor: University of Miami, MAPS
Clinical study Phase I begun (up to 2 mg/kg), funding ceased, published. view video

Last updated: Wed Apr 30 2003

MAPS Bulletin – Volume 6 Number 3 Summer 1996 Phase 1 Clinical Trial of Ibogaine in Human Patient Volunteers MAPS Bulletin – Volume 6 Number 1, Autumn 1995 Development of Ibogaine as an Anti-Addictive Drug: A progress report from the University of Miami School of Medicine MAPS Bulletin – Volume 5 Number 3 Winter 1994-95
Ibogaine in the treatment of chemical dependence disorders: clinical perspectives

Ketamine Research Ketamine Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Ketamine Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Ketamine Studies: Completed

Meditation with Salvia Divinorum/Salvinorin A (link to page)

Meditation with Salvia Divinorum/Salvinorin A

Investigators: Ian Soutar, Rick Strassman, M.D.
E-mail: soutar@horizon.bc.ca
Sponsor: MAPS

Ketamine Psychedelic Therapy In The Treatment of Heroin Addiction
Investigator: Evgeny Krupitsky MD, PhD., St. Petersburg, Russia
Contact:
Sponsors: MAPS, Heffter
In this study, forty patients will be given 3 therapy sessions with ketamine, while another forty patients will be given 3 therapy sessions, one with ketamine and two without ketamine. MAPS and Heffter Research Institute have jointly agreed to donate $9,450 each for five years to this study. MAPS and Heffter have already donated for each of the first four years. Fifty-nine patients have already been treated, and follow-up assessments have been performed on patients already enrolled in this study so far. Unfortunately ketamine has recently been rescheduled in Russia and this study has been shut down. Dr. Krupitsky is trying to reopen the study but isn’t sure yet whether this can be accomplished.
Research Protocol for Single vs. Multiple Dose Study

Last updated: Fri Apr 13 2007

Ketamine Research in Russia Page (MAPS)
Krupitsky E, Burakov, A, Romanova, T, Dunaevsky, I, Strassman, R, Grinenko A (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23, 273-283. Krupitsky, EM, Burakof AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY (2007). Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence. J Psychoactive Drugs 39(1): 13-19. Evegeny M. Krupitsky, M.D., Ph.D., Andrey M. Burakov, M.D., Ph.D., Tatyana N. Romanova, Ph.D., Nina I. Grinenko, M.D., Alexander Y. Grinenko, M.D., Ph.D., Jason Fletcher, M.A., Ismene L. Petrakis, M.D., and John H. Krystal, M.D. (2001). Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men: Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists. Neuropsychopharmacology 25(6): 936-947

Experiments in Altered Perception of 3-D Visual Illusions as a Screening Method for Psychedelic Activity Using Ketamine
Investigators: Torsten Passie, MD; Udo Schneider MD and Hinderk Emrich, MD
Hannover, Germany
Contact:
www.schamanismus-information.de
Sponsor: MAPS, Dept. of Psychiatry Hannover Medical School
Clinical experiment with ketamine to establish a paradigm to use visual 3-D illusions as screening instruments for detecting psychedelic activity in humans below the subjective threshold of experience. Passie’s team has recently published a report relating to this research. A second report on data from this MAPS-supported study will soon appear in the journal “Neuropsychobiology” in early 2005.

Last updated: Mon Feb 21 2005 Passie T, Karst M, Borsutzky M, Wiese B,
Emrich HM, Schneider U (2003)Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man. J Psychopharmacology 17: (2003) 51-56 Full Text in PDF Format

Ketamine Psychedelic Therapy in the Treatment of Heroin Addiction
Investigator: Evgeny Krupitsky, MD, PhD
St. Petersburg, Russia
Contact
Sponsor: MAPS, Heffter
Clinical study, drug administration phase completed, 70 patients treated
(35 in the experimental and 35 in the control group). The study is
finished, the researchers published the six-month follow-up paper
in MAPS. The one-year follow-up analysis has been completed. Two year
follow-up data has been analyzed and submitted for publication and is
currently in the midst of the peer review process. Results are promising.

Research Protocol for the Therapeutic dose vs. Low Dose Placebo study

Last updated: Tue May 6 2003

Antidepressant effects of ketamine in depressed patients
Investigators: Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH
Abraham Ribicoff Center Clinical Neuroscience Research Unit of
theConnecticut Mental Health Center, New Haven 06519, USA
Seven
subjects with major depression completed 2 test days that involved
intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline
solutions under randomized, double-blind conditions. RESULTS: Subjects
with depression evidenced significant improvement indepressive symptoms
within 72 hours after ketamine but not placebo infusion. CONCLUSIONS:
These results suggest a potential role for NMDA receptor-modulating
drugs in the treatment of depression.
Last updated: Wed Apr 12 2000

Reference: Biol Psychiatry 2000 Feb 15;47(4):351-4.

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations
Investigators: Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-
Byrne PP
Department of Psychiatry, Harborview Medical Center, University of Washington, Seattle
Contact:
Ketamine or saline was administered in a single-blinded crossover protocol to 10 psychiatrically healthy volunteers. Hallucinogen rating scale scores were similar to those found in a previous study with psychedelic doses of DMT. Synopsis of paper in Anesthesiology (1998)

Last updated: Wed Nov 3 1999

Ketamine Psychedelic Therapy in the Treatment of Alcoholics
Investigator: Evgeny Krupitsky, MD, PhD
St. Petersburg, Russia
Contact:
Sponsor: Leningrad Regional Center for Alcoholism and Drug Addiction Therapy, MAPS
Ten years of clinical studies completed and published.

Last updated: Fri Apr 9 1999 Krupitsky E.M., Grinenko A.Y.
Ketamine psychedelic therapy (KPT): a review of the results of ten years of research.
Journal of Psychoactive Drugs, 1997, Vol. 29, N.2, pp.165-183.

Ketamine Research in Russia Page (MAPS)

>

LSA Research LSA Studies: In Progress

Case Series: Response of Cluster Headache to Self-Administered Lysergic-Acid-Amide-Containing Seeds
Investigator: R. Andrew Sewell MD
Contact:

Sponsor: MAPS
Inspired by reports from the cluster headache community that ingestion
of seeds containing LSA (Hawaiian baby woodrose, morning glory, Rivea
corymbosa) terminates cluster periods in the same way that LSD and
psilocybin do, this study will examine the effects of LSA on cluster
headache by collecting accounts from patients who have used these
seeds to control their symptoms, and will also analyze the seeds that they
used in order to determine the LSA content.
Sewell AR, Reed K, Cheng J, Li S-M, Cunningham M (2008) Response of cluster headache to self-administration of seeds containing lysergic acid amide Poster, Last updated: Tue Dec 9 2008

LSA Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

LSA Studies: Completed

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

LSD Research LSD Studies: In Progress

LSD-assisted psychotherapy for 12 people with anxiety related to life-threatening illness
Investigator: Peter Gasser MD
Sponsor: MAPS
Contact:
This research will study the safety and efficacy of LSD-assisted psychotherapy in reducing anxiety arising from diagnosis with a serious illness and limited life expectancy, to be conducted in 12 subjects in Switzerland by Dr. Peter Gasser. The protocol was reviewed and approved by the ethics board and was reviewed and cleared by Swissmedic, the Swiss Food and Drug Agency, and has been reviewed and cleared by BAG, the agency akin to the US Drug Enforcement Administration. Dr. Gasser sent in his first annual report on November 25, 2008 and has enrolled four subjects.
Last updated: Tue Dec 9 2008

Gasser P. Planning LSD Research in Switzerland – MAPS Bulletin 16(2): 10

Swiss LSD/End-of-Life Anxiety Study Annual Report Completed:

On November 25, 2008, Dr. Peter Gasser, the Principal Investigator (PI) for the MAPS-sponsored LSD/end-of-life anxiety study, issued the first Annual Report discussing the progress we’ve made in this last year. We’re making gradual progress in what will become the first study of the therapeutic use of LSD in almost 40 years.

Read this letter from MAPS researcher Peter Gasser discussing his recently approved Swiss LSD-End of life study.

LSD Studies: Under Development

Psilocybin and LSD in the treatment and prevention of cluster headaches
Investigators: Dr. John Halpern
Location: Harvard Medical School, McLean Hospital, Belmont, MA.
Sponsor: ClusterBusters
Contact:
MAPS was approached in early 2004 by Bob Wold, a cluster headache patient advocate (http://www.clusterbusters.com), who has collected more than 50 case reports of people reporting very positive results in breaking cluster headache cycles and delaying the reoccurrance of cluster headaches through using psilocybin or LSD. At present, there are some medications that are used to stop cluster headaches, which are more severe than migraines, but they are not fully effective in many patients, and they do not prevent the cycling course of cluster headaches.

Marsha and David Weil have donated $50,000 for this research effort and Joseph Leonard has donated $2,000. An estimated $250,000 in addition is being sought to support this clinical trial. Potential donors can contact at Clusterbusters for more information. The effort to design and obtain approval for a study will be led by Dr. John Halpern at Harvard Medical School. Protocol development is still underway. Dr. Sewell and Halpern have completed and published a case series of people with cluster headaches who used psilocybin or LSD to treat their condition.

Last updated: Mon Dec 3 2007

Sewell RA, Halpern JH, Pope HG Jr. (2006) Response of cluster headache to psilocybin and LSD. Neurology 27;66: 1920-1922.

LSD Studies: Completed

Since the discovery of the psychoactive effects of LSD in 1943, over 1000 papers have been published on a huge range of effects of LSD in humans and animals. See the Psychedelic Bibliography for more on these studies. You may also view references from Torsten Passie’s psychedelic/psycholytic therapy database, also accessible through the psychedelic bibliography. To view this collection, either search “entire collection,” or use “Expert search” and type “passie” as the requested database.

Receptor Profiles of Lysergamides related to LSD
Investigator: David E. Nichols, PhD
Purdue University – West Lafayette, IN
Contact:
Sponsor: Heffter, Promind
Laboratory research, no human or animal subjects. It is well known that the nature of the amide function of lysergamides is critical to conferring activity and high potency onto these molecules. The N,N-diethylamide (LSD) is unique among all the known amides, both for the qualitative aspects of its effects and for its extremely high potency.This project is evaluating a series of lysergamides of varying amide structure using radioligand competition studies at cloned human brain neurotransmitter receptors expressed in cell lines. The project seeks to identify in these data the possible reasons for the high degree of variability in activity of the various amides. That is, is there a specific subset of receptors to which LSD binds that less potent lysergamides do not? In addition, intracellular signaling pathways are being examined to determine whether all lysergamides activate the same intracellular biochemical events.

Last updated: Mon Mar 9 2009

Follow-up study of Bastiaans LSD therapy
Investigators: Nicole Maalste, Hans Ossebaard
Utrecht, Netherlands
Contact:
Sponsor: MAPS, Promind Foundation
Retrospective survey study with former clients who were treated with
drug therapy by Dr. Jan Bastiaans. Data collection and analysis for
pilot study completed. Funding sought for further research.
Last updated: Mon Mar 25 2002

Final Report: Summer 1999. Progress Report: Winter 1999. Winter 2001.

Psycholytic Therapy with MDMA and LSD in Switzerland
Zurich, Switzerland
Investigators: Marianne Bloch, MD, Jurai Styk, MD and Dr. Samuel Widmer, MD
Sponsor: Swiss Medical Society for Psycholytic Therapy
From 1988 to 1993 therapists with the Swiss Medical Society for Psycholytic Therapy worked with MDMA and LSD as adjuncts to psychotherapy. The findings from this study were published in the MAPS Bulletin, Winter 1994-
95. Drs. Juraj and Sonja Styk discussed this work at the 1999 MAPS MDMA symposium in Israel. Read their talk, view video

Last updated: Fri Jan 14 2000 A Critical Review of Theories and Research Concerning LSD and Mental Health David Abrahart Psychedelic-Assisted Psychotherapy for the Terminally Ill
Bruce Sewick

A Critical Review of Theories and Research Concerning Lysergic Acid Diethylamide (LSD) and Mental Health
Investigator: David Abrahart
Contact:
A critical research literature review concerning LSD and mental health. In particular it concentrates on flashbacks, precipitated psychoses and therapeutic uses. Read it

Last updated: Wed Aug 25 1999

Follow-up study of Janiger LSD research
Investigators: Rick Doblin, Jerry Beck, PhD, Kate Obata, Maureen Alioto
Los Angeles Area, California
Contact
Sponsor: MAPS
Retrospective survey study with 45 people who participated in the LSD
research of Dr. Oscar Janiger between 1954 and 1962. The Janiger LSD Follow-up Study was published by MAPS.

Last updated: Sun May 9 1999

Mescaline Research Mescaline Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Mescaline Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Mescaline Studies: Completed

Blood flow and cerebral laterality in the mescaline model of psychosis
Investigators: Hermle L, Gouzoulis-Mayfrank E, Spitzer M
Department of Psychiatry, Christophsbad, Goppingen, Germany.
Abstract of published paper
Last updated: Tue Feb 22 2000

Peyote Research Peyote Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Peyote Studies: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Peyote Studies: Completed

Peyote Neuropsychological Study
Investigator: John Halpern, MD, Harrison Pope, MD
Harvard Medical School – Cambridge, Massachussetts
Contact:
Sponsor: Heffter, NIDA, Harvard Medical School, MAPS
Investigators have begun neuropsychological testing with Native American Church members. The investigators did not find any signs of impaired cognition in NAC members. MAPS donated $10,000 towards this study in May, 2001.

Last updated: Wed Feb 25 2009 MAPS Bulletin — Volume 11, Number 2 Fall 2001. “Research at Harvard Medical School” — by Dr. John Halpern
“Interview with John Halpern” — by Valerie M.
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychi. 58(8):624-631.

Psilocybin Research Psilocybin Studies: In Progress

Johns Hopkins Study of Psilocybin in Cancer Patients
Investigators: Roland Griffiths PhD, William Richards PhD, Matthew Johnson, Ph.D., Una McCann, M.D.
Sponsor: Heffter Research Institute, Riverstyx Foundation
Contact:
This study is being done to find out if psilocybin can produce personally and spiritually meaningful experiences in cancer patients, thereby extending findings from an earlier study in our laboratory with healthy volunteers. This could be important because spirituality has been associated with increased psychological coping and decreased depression in serious illness. The study will enroll about 44 people, who will receive careful preparation and 2 sessions in which they will receive psilocybin. Structured guidance will be provided during the session and afterward to facilitate integration of the experiences.

Last updated: Wed Mar 4 2009

To learn more about this study, visit the study website: http://www.cancer-insight.org

Psilocybin in the treatment of cancer patients
Investigator: Charles Grob, MD, UCLA-Harbor Medical Center – Torrance, CA
Contact:
Web: www.canceranxietystudy.org
Sponsor: Heffter
Grob has prepared a study investigating whether anxiety in the dying can be significantly reduced by the appropriate administration of psilocybin. Any attendant reduction in pain will also be measured. This study has enrolled 12 participants and all participants completed the study. The study is no longer recruiting participants.

Last updated: Tue Jan 6 2009

“The Hallucinogenic Way of Dying” Judith Lewis, LA Weekly

Effects of Psilocybin on Healthy Volunteers
Investigators: Roland Griffiths PhD, William Richards PhD, Una McCann MD, Robert Jesse
Sponsor: NIDA, Council for Spiritual Practices, Heffter Research Institute
Contact:
A series of studies is planned to investigate the effects of psilocybin in healthy volunteers. The first was a double-blind study evaluating the psychological effects of 30 mg/70 kg psilocybin relative to methylphenidate, 40 mg/70 kg administered under comfortable, supportive conditions to 36 hallucinogen-naive adults reporting regular participation in religious or spiritual activities. After psilocybin, 61% of the volunteers met pre-established criteria, as measured on standardized scales, for a full mystical experience, and 31% reported significant fear sometime during their psilocybin session. Two months after sessions, 71% of the volunteers rated their psilocybin experience as among the five most “spiritually significant” experiences of their lifetimes. Seventy-nine percent of volunteers rated that it had increased their current sense of personal well being or life satisfaction. Community observer (family, friends, coworkers) ratings tended to confirm this. Fourteen month follow-up data is being analyzed.

Continuing support for this research program is uncertain and the investigators are attempting to network with individuals or foundations that could help provide support. Learn more about this research: http://www.bpru.org/jhscrp_letter.pdf

Last updated: Fri Aug 1 2008 Griffiths RR, Richards WA, McCann U, Jesse R. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187(3):268-283.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 22(6):621-632.

Psilocybin Effects on Attention, Perception and Cognition
Investigators: Franz Vollenweider MD, Olivia Carter PhD, Felix Hasler MD
Psychiatric University Hospital, Zurich, Switzerland…
Contact:
Sponsor: Heffter
Dr. Vollenweider and colleagues continue to study the neural correlates of consciousness and the effects of psilocybin on visual perception, attention, working memory, and time perception. Other studies will use EEG or positron emission tomography (PET) imaging.. Several published reports describe research findings, and other reports are forthcoming, or studies are underway at present.
Last updated: Fri Apr 13 2007

Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport 15:1947-1951. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. (2005) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30: 1154-1162.
Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. (2005) Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors. J Cogn Neurosci 17:1497-1508.
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21 50-64.
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007 Published online before print.

Experimental Studies on the Effects of Psilocybin on Binocular Depth Inversion, Binocular Rivalry, Neuropsychology and Synaesthesias
Investigators: Torsten Passie M.D., Jrgen Seifert M.D., Udo Schneider M.D.,
Hinderk M. Emrich M.D., Ph.D.
Medical School Hannover, Dept. of Clinical Psychiatry and Psychotherapy, Hannover, Germany
Contact:
Web: www.schamanismus-information.de
Sponsor: MAPS/Medical School Hannover, Dept. of Clinical Psychiatry and Psychotherapy
This is a randomized, double-blind, active placebo-controlled study of the effects of medium doses of psilocybin in 12 healthy physicians, examining the effects of psilocybin on different neuropsychological measures, perceptual changes, synaesthesias and some subjective effects. These measures include binocular rivalry (different, or conflicting, information presented to each eye) and the “hollow mask” paradigm, measures examining changes in central processing of
visual perception. The study is fully approved. MAPS has donated $3,000 for the purchase of 250 milligrams of psilocybin, insurance, and other expenses. Six of twelve
subjects have now been enrolled in this study. So far, subjects have not experienced any complications. The setting is designed so that subjects have some quiet times for self-exploration. It seems that they have had some healing passages in their experiences. Our plan is to complete the study in the second half of 2007.
Read more about this study
Last updated: Fri Mar 9 2007

Psilocybin Studies: Under Development

Psilocybin and LSD in the treatment and prevention of cluster headaches
Investigators: Dr. John Halpern
Location: Harvard Medical School, McLean Hospital, Belmont, MA.
Sponsor: ClusterBusters
Contact: MAPS was approached in early 2004 by Bob Wold, a cluster headache patient advocate (http://www.clusterbusters.com), who has collected more than 50 case reports of people reporting very positive results in breaking cluster headache cycles and delaying the re-occurrance of cluster headaches through using psilocybin or LSD. At present, there are some medications that are used to stop cluster headaches, which are more severe than migraines, but they are not fully effective in many patients, and they do not prevent the cycling course of cluster headaches

Marsha and David Weil have donated $50,000 for this research effort and Joseph Leonard has donated $2,000. An estimated $250,000 in addition is being sought to support this clinical trial. Potential donors can contact at Clusterbusters for more information. The effort to design and obtain approval for a study will be led by Dr. John Halpern at Harvard Medical School. Protocol development is underway for this study.
.

Last updated: Fri Apr 13 2007

Sewell RA, Halpern JH, Pope HG Jr. (2006) Response of cluster headache to psilocybin and LSD. Neurology 27;66: 1920-1922.

Psilocybin Studies: Completed

There is a long history of human research with psilocybin, with a large number of publications in the area of psilocybin research. See the Psychedelic Bibliography to view these studies.

Psilocybin in the Treatment of Obsessive-Compulsive Disorder
Investigator: Francisco Moreno, MD
University of Arizona, Tucson, USA
Contact:
Sponsor: Heffter/MAPS
This is the first FDA-approved study in more than 25 years to examine the use of psilocybin in a patient population. The principal investigators plan to study the use of psilocybin in 10 patients suffering from obsessive-compulsive disorder (OCD). They want to determine if they can replicate in a clinical study several published case reports of patients whose OCD symptoms were reduced after self- experimentation with psilocybin mushrooms. MAPS has paid $12,250 for the synthesis of one gram of psilocybin. Analytical data on this psilocybin has been submitted to FDA in March, 2001, with approval obtained from the FDA on May 9, 2001. DEA licenses received July 2, 2001. First patient was treated on November 27, 2001, and after enrolling nine subjects, the study is now complete. Dr. Moreno’s research team is now looking at the data, and a publication will be forthcoming. Preliminary analyses have been performed, and the data has been presented at the Society of Biological Psychiatry, The American College of Neuropsychopharmacology, the New Clinical Drug Evaluation Unit, and the International Transpersonal Association (ITA) Annual Meetings. Current news
on this study, Study Protocol, Informed Consent Form

Last updated: Wed Feb 9 2005

Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychi 67: 1735-1740.

Psilocybin: Basic Dose-Response Safety Studies
Investigator: Franz Vollenweider, MD
Psychiatric University Hospital Zurich, Switzerland
Contact:
Sponsor: Heffter
Dr. Vollenweider’s team have completed a series of basic research studies into the dose-response effects of psilocybin on physiological and psychological measures, cognition, sensorimotor gating, sequential behaviour, and brain activity in healthy human subjects. Fifty-six individuals were examined after a range of doses of psilocybin. A paper reporting the effects of placebo, very low, low, medium and high doses of psilocybin (45 -315 mcg/kg) in eight individuals has been published on-line in November 2003 and in print in March 2004. The researchers assessed subjective, physiological and neuroendocrine effects of psilocybin, including an assessment of attention and visual perception, and previous investigations have examined the contribution of serotonin and dopamine transmitter sytsems to producing the subjective effects of psilocybin.

Last updated: Thu Mar 18 2004

Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. (2002) Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal. 30: 331-339. Hasler F , Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172: 145-156. Published on-line DOI: 10.1007/s00213-003-1640-6
Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, Koller R. (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 28(1):170-181. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902. Vollenweider FX, Vontobel P, Hell D, Leenders KL. (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride. Neuropsychopharmacology 20:424-433.

The Concord Prison Experiment Experiment Follow-Up
Investigator: Rick Doblin, Ph.D.

This study, originally published in the Journal of Psychoactive Drugs [Oct-Dec 1998] is one in a series of long-term follow-ups to early psychedelic research that MAPS has sponsored. The original 1961-63 Harvard study lead by Dr. Timothy Leary investigated the utility of psilocybin in reducing rates of recidivism for prisoners.

Last updated: Mon Jan 3 2000

Article from MAPS Bulletin
Leary Riedlinger Report

The Good Friday Experiment Follow-Up
Investigator: Rick Doblin, Ph.D.
Contact:
This study, originally published in the Journal of Transpersonal Psychology [1991 Vol 23(1)] is one in a series of long-term follow-ups to early psychedelic research that MAPS has sponsored. The original 1962 Harvard study lead by Walter Pahnke investigated the utility of psilocybin in triggering a mystical experience.

Last updated: Mon Jan 3 2000

Doblin R (1991) Pahnke’s “Good Friday Experiment”: A Long-Term Follow-Up and Methodological Critique. J Transpersonal Psychol 23(1).

Psilocybin’s effects on cognition
Investigator: Manfred Spitzer, MD, PhD et al.
Psychiatrische Universitats Klinic, Heidelberg, Germany
Human clinical study, completed and published. More psilocybin research in Germany
Last updated: Fri Apr 9 1999 Spitzer M, et al. (1996)
Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 1996 Jun 15;39(12):1055-7. Psilocybin’s effects on cognition: Recent research and its implications for enhancing creativity — MAPS Bulletin, Volume 7, Number 1 Winter 1996/97

Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD
University of New Mexico, USA

Psychobiological study. Phase 1 dose-response study
Sponsor: NIDA
Begun, not completed due to personal reasons unrelated to study itself.

Last updated: Fri Apr 9 1999 University of New Mexico Update — MAPS Bulletin, Volume 6, Number 1 Autumn 1995

Salvia Divinorum Research Salvia Divinorum: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Salvia Divinorum: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Salvia Divinorum: Completed

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Multi-Drug Studies Multi-Drug Studies: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Multi-Drug Studies: Under development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Multi-Drug Studies: Completed

Differential Effects of Hallucinogens, Entactogens, and Psychostimulants
Investigators: Euphrosyne Gouzoulis-Mayfrank,Omega watch, MD and Mark Geyer, PhD
Aachen, Germany and UC San Diego – La Jolla, California
Contact:
Sponsor: Heffter
A study with healthy volunteers with two different hallucinogens and placebo in a double- blind, cross-over design. The aim of the study is to compare the effects of a classic tryptamine hallucinogen on psychosis-like psychopathology and measures of early information
processing to the effects of an NMDA-antagonist. References and details
Last updated: Wed Mar 4 2009

Receptor Mechanisms Contributing to Psychedelic Drug Effects
Investigators: Franz Vollenweider, MD and Mark Geyer, PhD
Sponsor: Heffter
Psychiatric University Hospital – Zrich, Switzerland and UC San Diego – La Jolla, California
Contact: ,
Last updated: Wed Mar 4 2009

Cross Cultural and Meta-Analysis Research Cross Cultural and Meta-Analysis: In Progress

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Cross Cultural and Meta-Analysis: Under Development

MAPS is currently unaware of any research studies that belong in this category. If you know of a study that should be listed here please send an email to .

Cross Cultural and Meta-Analysis: Completed

A Biochemical Bridge to the Embodied Psyche:

(doctoral dissertation)
Investigator: Kim Hewitt
Department of American Civilization, University of Texas at Austin
Contact:
Sponsors: MAPS
Exploration of how psychedelics helped facilitate a shift in American
ideas about mind- body interaction. In 1999 the investigator traveled to
the American Medical Archives in Chicago, and the Rockefeller Institute
Archives in Tarrytown, New York to do research for this project, and
presented part of her research on LSD at St. Lawrence University in
Canton, New York for a series called “Visions the Plants Gave Us.” Part
of my dissertation will be published in an anthology called “The
Politics of Healing,” to be published in 2002. My essay addresses how
psychedelic therapy changed individuals and the cultural mindset during
the 1950’s-60’s.

Last updated: Thu May 24 2001 Read the investigator’s essay “Solvents of Conceptual Sludge:
Psychedelic Therapy Confronting the Cold War Mindset.”
Read about this study in the MAPS Bulletin

Yes, Mom Took Acid: The Sociohistorical Influence of Prior Psychedelic Drug
(doctoral dissertation)
Investigator: Mariavittoria Mangini, M.S. PhD
Laytonville, California
Contact:
Qualitative study, using focused interviews to obtain narrative data.
Data also considered: published contemporary and historic discourses
about psychedelic drug use, accounts of the interactions of psychedelic
drug users with their social environment; and representations of the
psychedelic experience in art, music, film and the electronic media.

Mangini was one of fifty scholars nationwide awarded the American Dissertation Fellowship by the American Association of University Women for the 1999-2000 academic year, a heartening acknowledgement of the relevance of this topic.

Last updated: Wed Apr 11 2001

Northwest Amazonian Ayahuasca Shamanism and Near-Death Experience
Investigator: Marcus Lumby, PhD candidate
Contact:
Sponsorship: includes small grant from MAPS
Anthropological investigation, first phase completed.
Last updated: Thu Jun 8 2000

Field Reports and MAPS article.

Guided, Structured, Group Use of Entheogenic Substances in Western Culture
(doctoral dissertation)
Investigator: Roger Marsden
California Institute of Integral Studies, Clinical Psychology
Contact:
Sponsors: 1998 Kranzke Scholarship; MAPS
What are the different frameworks being employed by entheogenic guides?
How are these frameworks different from those used in the research of
the 1960s? How do the variations in present day frameworks appear to
affect the outcome? Regardless of one’s individual assumption of the
value of psychedelic work, it is happening in a variety of contexts
across the planet. The investigator has completed all interviews in 3
guided, structured entheogen/psychedelic groups. Data anaysis is
complete (10 central themes extracted for the basis of discussion, i.e.,
preparation, integration, relationship of participants to guide, role of
relationship of participants to each other, description of the actual
sessions, relationship of the work to drug abuse issues, etc.)
Last updated: Wed Jan 19 2000

Read about this study in the MAPS Bulletin

   Creative Commons 2009   MAPS   309 Cedar Street #2323   Santa Cruz, CA 95060-9989   tel: 831-429-MDMA (6362)   fax: 831-429-6370   askmaps@maps.org
相关的主题文章：

• Gulf Research Center – Home Page
• IARC – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
• IOL Home – INFORMS.org

  Home |  About RCUKRCUK Aims & OrganisationRCUK Strategy UnitResearch Councils Joint Units and ServicesSupplying goods and services to the Research CouncilsRCUK Executive GroupMembershipSubgroupsTerms of ReferenceRCUK Delivery PlanEvidence to inquiries and consultationsConsultationsEfficiency & effectivenessBetter services for the research communityEconomic Impact Reporting Frameworks (EIRF)Improving operational performanceManaging demand for research fundingRCUK Assurance ProgrammeResearch administrationResearch Councils Environmental Policy StatementResearch Councils Libraries & Inforrmation ConsortiumResearch OutcomesTerms and Conditions of Research Council fEC GrantsTerms and Conditions of Research Council Training GrantsPublicationsCorporate publicationsPolicy documents and reportsPerformanceParliamentary scrutiny 2005RCUK Review 2003RCUK Review 2004HistoryQuinquennial Review (QQR)RCUK launch eventRCUK Office in India launch eventRCUK Office in the US launch event | About the Research CouncilsActivitiesResearchTrainingKnowledge transferPublic Engagement with ResearchGovernment FundingDual support systemScience BudgetUK strategy for science and innovationGovernment Spending ReviewsGovernanceCouncil membershipOperationOperational performanceResearch strategiesResearch Highlights | RCUK FrameworkHealthy SocietyProductive EconomySustainable World |  Search  

Research
 

Innovation
 

Research Careers
 

International
 

Public Engagement with Research
 

Knowledge Transfer Portal
&nbsp,wedding dresses;

 

  Welcome to Research Councils UK

Welcome to the website for Research Councils UK, the strategic partnership of the UK’s seven Research Councils.

Each year the Research Councils invest around £2.8 billion in research covering the full spectrum of academic disciplines from the medical and biological sciences to astronomy, physics, chemistry and engineering, social sciences, economics, environmental sciences and the arts and humanities.

Many activities are undertaken collectively and this site aims to give comprehensive and up to date information on the progress of cross-Council activities and to provide a portal into individual Councils support for research, training, knowledge transfer and public engagement. Follow the left hand links to find out more.

The About the Research Councils menu provides links to information on how the Research Councils operate and the role they play in helping to deliver Government’s objectives for science and innovation. Follow the About RCUK menu to find out more about how the Councils work together, for example in providing submissions to consultations and Parliamentary inquiries.

  What’s New

View all news items | RSS

RCUK welcomes outcomes of REF ConsultationResearch Councils UK (RCUK) today welcomes the announcement of the outcomes of the Research Excellence Framework (REF) consultation. RCUK has worked closely with the Funding Councils to ensure that proposals for the REF will be effective in pursuing shared objectives, particularly in terms of rewarding excellent research and its impact.26/03/10

Online survey to evaluate the Beacons for Public Engagement (BPE) Initiative UK higher education staff and researchers are invited to take part in a new online survey to evaluate the RCUK Beacons Public Engagement (BPE) Initiative. The closing date for entering the survey has now been extended to Friday 9th April 201024/03/10

RCUK sponsors two awards at National Science and Engineering Competition 2010 Research Councils UK (RCUK) has sponsored the ‘Best Use of Research’ prizes at this year’s National Science and Engineering Competition 2010. One prize was awarded to an individual and the other to a team for outstanding use of research to help solve a problem.19/03/10

 

Research Councils UK Strategy Unit
Polaris House
North Star Avenue
Swindon, SN2 1ET

For detailed information about contacting the Research Councils see the contacts section.

    Help | Contacts | Disclaimer | Logos | How to Reach Us | Freedom Of Information     Research Council Links  

AHRC website  |  AHRC overview

   

BBSRC website  |  BBSRC overview

   

EPSRC website  |  EPSRC overview

   

ESRC website  |  ESRC overview

   

MRC website  |  MRC overview

   

NERC website &nbsp,Rolex Watch;|  NERC overview

   

STFC website  |  STFC overview

 
Pathways to Impact Website

 

Related Links

&#8226,gucci; RCUK Extranet (provided for Research Council staff)
• Joint Electronic Submission (Je-S)

Research Councils UK Reviews

• Governance of Good Research Conduct
• RCUK Review of UK Physics
• Review of fEC
• STFC Organisational Review
• RCUK Review of Energy 2010
• RCUK Review of e-Science

     
相关的主题文章：

• Babies are born to dance, new research shows
• Improbable Research » Page not found
• Cerebral Palsy Hope Through Research National In

We are here to help. Contact us.

Products Interconnection Mobile Data Services Number Portability ENUM Routing Administration Next Generation OSS Planning & Engineering Fulfillment Service Assurance Service Delivery & Charging Bandwidth Manager Converged Application Server Converged Application Suite Converged Revenue Management Managed Services Personalized Advertising Real-Time Charging Real-Time Policy Products by Name Services Common Language Consulting Education &amp,Tiffany Jewelry; Training Generic Requirements Implementation Managed / Hosted Network Element Provider Testing Transaction Services by Name Solutions Converged Charging Enterprise Services Mass Market Broadband Mobile Broadband Mobile Business Mobile Marketing & Advertising Next Generation Prepaid Order-to-Cash Plan-to-Provision Real-Time Enablers for
SOA Applications Service Delivery in the IMS
Environment Trouble-to-Resolution Wireless Operations Innovation Research Strategic Research Program Industry Leadership Thought Leadership Research Highlights Industry Applications Telematics Diagnostics & Prognostics Healthcare Mobile Messaging Financial Services Network Operations Data Reconciliation & Analysis IP Network
Assessment & Awareness Mobile Network Optimization Advanced Networks Wireless Mobile Networking Broadband Network Security Policy Management Wireless Security About Us Leadership Awards & Recognition News Press Releases Media Coverage Press Kit Events Events & Webinars Speaking Engagements Partners Worldwide Offices Investor Information Careers Suppliers Success Next Generation OSS Service Delivery & Charging Interconnection Research Profit From Telcordia Innovation

Leading global provider of fixed, mobile and broadband communications software and services

>> more

–>
Consulting

Helping organizations worldwide resolve their most complex communications challenges

>> more

–> Next Generation OSS

The foundation of superior business performance

Learn More >>

Service Delivery & Charging

Stand out from the crowd

Learn More >>

Interconnection

Deliver a seamless user experience

Learn More >>

Research

Solving real-world problems with advanced solutions and services

Learn More >>

latest news     Telcordia Research Spotlights Challenges with SMS/MMS Routing Delivery Telcordia Comments on FCC National Broadband Plan Telcordia Identifies Key Power Requirements for Next-Generation Telecom Networks Dr. Adam Drobot Appointed to Intelligent Transportation Systems Program Advisory Committee Telcordia Extends IBM Relationship for Next Generation OSS View All News  –> –> Consulting Services

For your entire
project lifecycle

Learn more >>

Engaging Advertisers:
Pragmatic Approaches to a
New Telecom Business Model

–>     Customer Success

Hear how Telcordia’s Next Gen OSS helped GISDATA Group
reduce order-to-service time for T-Com Croatia

Order-to-Cash

The workflow at the heart of every telecom business

IP Assure

Automated Network Error Detection and Remediation

Thought Leadership

The Case for Deep Configuration Assessment of IP Networks

Trouble-to-Resolution

Reducing Problems and Speeding Repair Time

Thought Leadership

Trouble-to-Resolution: Fewer and Faster

Customer Success

T-Com Croatia selects Telcordia to help it prepare for full market deregulation

Next Generation Prepaid

A powerful rating and charging solution for all your services

<!– Order-to-Cash

The workflow at the heart of every telecom business

Join the Conversation

Read Adan Pope’s blog in B/OSS: Free Is Fun, But Paid Needs a Reliable Platform

–> <!– Customer Success

Telcordia helps Cincinnati Bell realize the potential of mass market broadband

Thought Leadership

Telcordia Contributes to National Broadband Plan Discussion

–>     upcoming events

April 21-22,wedding dresses, 2010 • Washington, DC

April 20-22, 2010 • Geneva, Switzerland

May 18-20,Rolex Watch, 2010 • Nice, France

The Elements of Success

© Telcordia Technologies, Inc.

Careers Product Support Sitemap Subscribe Legal

Telcordia on the Web

RSS YouTube Podcasts Facebook TelecomTV
相关的主题文章：

• Pfizer.com Pfizer the world’s largest research-
• Security Research & Defense
• Cerebral Palsy Hope Through Research National In

Scientists Postdocs Students Educators Media Alumni Faculty and staff Board of Associates   Search Site Find People Search by lab __________ F A C U L T Y David Bartel Iain Cheeseman Gerald R. Fink Rudolf Jaenisch Susan L. Lindquist Harvey F. Lodish Terry L. Orr-Weaver David C. Page Hidde Ploegh Peter W. Reddien David Sabatini Hazel L. Sive Robert A. Weinberg Richard A. Young __________ F E L L O W S Thijn Brummelkamp Andreas Hochwagen Paul Wiggins Defne Yarar __________ A F F I L I A T E M E M B E R S Dave Gifford   –>
    Whitehead news on demand     Yasemin Sancak receives Harold M. Weintraub Award (3/11) Whitehead again among Best Places to Work for postdocs (2/25) "Relaxation&quot,prom dresses; a critical step in vertebrate brain development (2/10) Chimp and human Y chromosomes evolving faster than expected (1/13) Small molecules found to protect cells in multiple models of Parkinson’s disease (12/28) Knockouts in human cells point to pathogenic targets (11/26) Jamming cell?s protein disposal shows how system works (10/26) Whitehead Member David Sabatini receives Paul Marks Prize (9/29) Whitehead Member Rudolf Jaenisch awarded Ernst Schering Prize (9/22) More News   Cancer MicroRNA Stem cells &nbsp,wedding dresses;
 
Whitehead Institute and MIT’s Biology Department are seeking an outstanding scientist at the Assistant Professor level

 
Fall 2009 Issue   High School Teachers Program Biology Week
&nbsp,gucci;
相关的主题文章：

• Archive of Nucleic Acids Research .
• Committee for Research and Exploration Grant Appli
• Scarborough Research In-depth insights on the sho

Advertisement,gucci bags
    Search: Advanced Search Circulation Research Archives Select an Issue Browse by Subject Circulation Research Resources Online Submission/
   Peer Review Instructions to Authors About Circulation Research Editorial Board Journal History Facebook Twitter RSS Feeds Feedback International Users Subscriptions and Services Free Sample Issue Subscriptions Permissions Classified Ads Help AHA Resources AHA Journals Home Scientific Statements Browse AHA Journals Council on Basic Cardiovascular Sciences
Impact Factor
9.989
March 19, 2010 (next issue online April 1) Editors’ Picks Homepage Editors Pick File TRPM7-Mediated Ca2+ Signals Confer Fibrogenesis in Human Atrial Fibrillation Full Text | PDF

Myozap,prom dresses, a Novel Intercalated Disc Protein, Activates Serum Response Factor朌ependent Signaling and Is Required to Maintain Cardiac Function In Vivo Full Text | PDF

Cardiac Progenitor Cell Cycling Stimulated by Pim-1 Kinase Full Text | PDF Current Issue Most Often Read Most Often CitedArchives Sign up for eTOCs Homepage Ahead of Print File PUBLISH AHEAD OF PRINT – ONLINE FIRST For the month of February 2010, the average time from submission to first decision for all original research papers submitted to Circulation Research was 15.6 days.

Defective DNA Replication Impairs Mitochondrial Biogenesis In Human Failing Hearts
March 25, 2010
Abstract | PDF

Voltage-Gated Sodium Channels Are Required for Heart Development in Zebrafish
March 25, 2010
Abstract | PDF

MAPK-Activated Protein Kinase-2 in Cardiac Hypertrophy and Cyclooxygenase-2 Regulation in Heart
March 25,wedding dresses, 2010
Abstract | PDF

Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 5 (Nox5) Regulation by Angiotensin II and Endothelin-1 Is Mediated via Calcium/Calmodulin-Dependent, Rac-1朓ndependent Pathways in Human Endothelial Cells
March 25, 2010
Abstract | PDF

More » Homepage Coverlines File FEATURED IN THIS ISSUE Robert Lefkowitz: Godfather of G Protein-Coupled Receptors
Extract | Full Text | PDF

NEWS & VIEWS Comparing Pumps
Extract | Full Text | PDF

Crucial Role of Nrf3 in Smooth Muscle Cell Differentiation From Stem Cells
Abstract | Full Text | PDF

Lack of Mitogen-Activated Protein Kinase Phosphatase-1 Protects ApoE-Null Mice Against Atherosclerosis
Abstract | Full Text | PDF

Transmural Dispersion of Repolarization in Failing and Nonfailing Human Ventricle
Abstract | Full Text | PDF

Relative Roles of Direct Regeneration Versus Paracrine Effects of Human Cardiosphere-Derived Cells Transplanted Into Infarcted Mice
Abstract | Full Text | PDF

More » Spotlight Homepage Spotlight File

Advertisement For faster access to AHA Journals Online from certain locations, use this URL: http://intl.ahajournals.org (More Information)

Privacy Statement | Legal Disclaimer | Copyright
Copyright © 2010 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.

Lippincott Williams & Wilkins publishes the AHA Journals for the American Heart Association Stanford University Libraries’ HighWire Press® assists in the publication of the AHA Journals Online
相关的主题文章：

• International Center for Research on Women (ICRW)
• Archive of Nucleic Acids Research .
• Climate Research News